Hypoxia in Lung Cancer Management: A Translational Approach
Julien Ancel, Jeanne-Marie Perotin, Maxime Dewolf, Claire Launois, Pauline Mulette, Béatrice Nawrocki-Raby, Véronique Dalstein, Christine Gilles, Gaëtan Deslée, Myriam Polette, et al.

To cite this version:
Julien Ancel, Jeanne-Marie Perotin, Maxime Dewolf, Claire Launois, Pauline Mulette, et al.. Hypoxia in Lung Cancer Management: A Translational Approach. Cancers, 2021, 13 (14), pp.3421. 10.3390/cancers13143421. hal-03325614

HAL Id: hal-03325614
https://hal.univ-reims.fr/hal-03325614
Submitted on 25 Aug 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Review

Hypoxia in Lung Cancer Management: A Translational Approach

Julien Ancel 1,2, Jeanne-Marie Perotin 1,2, Maxime Dewolf 2, Claire Launois 2, Pauline Mulette 1,2, Béatrice Nawrocki-Raby 1,2, Véronique Dalstein 1,3, Christine Gilles 4, Gaëtan Deslée 1,2, Myriam Polette 1,3,† and Valérian Dormoy 1,*,†

1 Inserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, 51092 Reims, France; jancel@chu-reims.fr (J.A.); jmperotin-collard@chu-reims.fr (J.-M.P.); pmulette@chu-reims.fr (P.M.); beatrice.raby@univ-reims.fr (B.N.-R.); vdalstein@chu-reims.fr (V.D.); gdeslee@chu-reims.fr (G.D.); myriam.polette@univ-reims.fr (M.P.)
2 Department of Respiratory Diseases, Centre Hospitalier Universitaire de Reims, Hôpital Maison Blanche, 51092 Reims, France; mdewolf@chu-reims.fr (M.D.); claunois@chu-reims.fr (C.L.)
3 Department of Biopathology, Centre Hospitalier Universitaire de Reims, Hôpital Maison Blanche, 51092 Reims, France
4 Laboratory of Tumor and Development Biology, GIGA-Cancer, University of Liège, 4000 Liège, Belgium; cgilles@uliege.be
* Correspondence: valerian.dormoy@univ-reims.fr
† These authors contributed equally.

Simple Summary: Hypoxia is a common feature of lung cancers. Nonetheless, no guidelines have been established to integrate hypoxia-associated biomarkers in patient management. Here, we discuss the current knowledge and provide translational novel considerations regarding its clinical detection and targeting to improve the outcome of patients with non-small-cell lung carcinoma of all stages.

Abstract: Lung cancer represents the first cause of death by cancer worldwide and remains a challenging public health issue. Hypoxia, as a relevant biomarker, has raised high expectations for clinical practice. Here, we review clinical and pathological features related to hypoxic lung tumours. Second, we expound on the main current techniques to evaluate hypoxic status in NSCLC focusing on positive emission tomography. We present existing alternative experimental approaches such as the examination of circulating markers and highlight the interest in non-invasive markers. Finally, we evaluate the relevance of investigating hypoxia in lung cancer management as a companion biomarker at various lung cancer stages. Hypoxia could support the identification of patients with higher risks of NSCLC. Moreover, the presence of hypoxia in treated tumours could help clinicians predict a worse prognosis for patients with resected NSCLC and may help identify patients who would benefit potentially from adjuvant therapies. Globally, the large quantity of translational data incites experimental and clinical studies to implement the characterisation of hypoxia in clinical NSCLC management.

Keywords: non-small cell lung cancer; hypoxia; HIF; angiogenesis; oxygen sensing; lung cancer management

1. Introduction

Lung cancer represents the leading cause of cancer-related deaths worldwide with 1,761 million deaths in 2018 and an incidence exceeding 2 million (11.6%), largely represented by non-small cell lung cancer (NSCLC) [1]. Lung cancer is diagnosed at a locally advanced or metastatic stage in most cases, leading to poor outcomes and no curative options [2]. In recent decades, many innovative strategies have been designed to improve patient survival rates, namely tyrosine kinase inhibitors (TKIs) of oncogenic alterations or immunotherapies [3]. On the one hand, personalised medicine has emerged from proof
of concept to current applications in clinical lung cancer management, but only a limited population harbours molecular targetable alterations and can benefit from this approach [4]. On the other hand, immunotherapies are now largely employed but obtain labile response rates with fewer than 40% of responders among a selected population [5]. Unfortunately, relapse and resistance fatally occur despite specific and adapted strategies. Consequently, global age-standardised 5-year survival remains within the range of 10–20% and a limited increase of up to 5% has been observed [6], arguing the need to further refine and improve clinical lung cancer management.

Hypoxia has been explored specifically in the context of cancer and numerous reports have suggested its potential clinical relevance. The deprivation of optimal oxygen supply at the cellular, tissular, or organ level, is a common feature observed in various physiological and pathological conditions, such as foetal and organ development or interstitial lung disease, chronic obstructive pulmonary disease (COPD), and pulmonary hypertension [7–13]. Moreover, hypoxia is considered a crucial factor in carcinogenesis [14,15]. Hypoxia appears to be a central key sensor at the forefront of major steps of cancer progression [16] including invasiveness, acquisition of stem cell properties [17], stimulation of angiogenesis and lymphangiogenesis [18], immune escape [19], radiotherapy sensibility, cell survival and resistance to apoptotic signals [20]. Angiogenesis and vasculogenesis are hallmarks of hypoxia-induced modifications [21], but the whole spectrum of molecular and cellular events including oxygen sensing and its signalling pathways are still only partially elucidated [22]. The majority of experimental investigations have been focusing on HIF-1α (hypoxia-inducible factor 1-alpha), the key transcriptional regulator of response to hypoxia [23].

Hypoxia has been identified as a key player in cancer progression and initiation in the context of breast cancer, endocrine tumours, brain tumours, or malignant haematopoiesis processes [24–28]. In this review, we discuss the potential relevance of considering and implementing hypoxia in clinical practice to improve personalised lung cancer management. We focus on NSCLC because of its higher frequency and extensive literature in the field of hypoxia, although some reports also highlight the potential involvement of oxygen starvation in small cell lung cancer [29] and malignant pleural mesothelioma [30].

2. Biological Features Associated with Hypoxia in NSCLC

In this first part, we will describe current clinical approaches for evaluating the hypoxic status and its pathological implications in lung cancer specimens. Oxygen electrodes and radionuclide measurements have been used in the past and are still employed despite many drawbacks in their use within clinical settings. Since the initial challenge for the pathologist is the identification of hypoxic tumours in NSCLC, we describe herein the main hypoxia-associated features from sub-cellular to tissue level.

2.1. Hypoxia-Inducible Factor Detection in Whole Tumour Tissues

Immunohistochemistry techniques exploring hypoxia usually rely on HIF-1α and pimonidazole staining [31,32]. The expression of HIF-1 inducible markers and the production of nitroimidazoles are triggered by different oxygen concentrations and HIFs can also be induced in physiological hypoxic conditions [33]. Although HIF-1α is most frequently examined to define hypoxic tumours, multi-marker strategies have been implemented previously and based on HIF sub-cellular pathways. In normoxia, the HIF-α subunit is perpetually degraded by the von Hippel-Lindau (VHL) ubiquitination followed by proteasome degradation [34]. Oxygen deprivation inhibits this process and leads to HIF-α stabilisation, an increase of cytosolic concentration, and heterodimerization with β sub-units. Then, the recruitment of co-activators such as CBP (CREB binding protein) or p300 form a transcription complex that bind the promotor region of hypoxia target genes (containing RCGTG sequence especially). Upregulated genes interfere with several biological processes including metabolism (via GLUT-1 (glucose transporter-1) or CA-IX (carbonic anhydrase IX), neo-angiogenesis (via VEGF, vascular endothelial growth factor),
epithelial to mesenchymal transition (via vimentin), cancer stem cells (CSC) induction and maintenance (via Sox2), cancer cell migration and invasion (via TGF-α, transforming growth factor-α), and inflammatory mediator production (via IL-6) \[35\]. HIF-2α and other inducible factors such as Ang-2 (angiopoietin-2), FGF (fibroblast growth factor) or insulin-like growth factors have also been studied and alternative robust hypoxia markers have been evaluated \[36–45\]. A meta-analysis, conducted on 17 NSCLC histological studies, extensively described clinical-pathological features associated with hypoxia through HIF-1α and/or VEGF \[38\]. In this report including 2056 patients, no association was noticed with tumour grade differentiation. Comparing histological sub-types, adenocarcinoma (AC) expressed lower levels of HIF-1α than squamous cell carcinoma (SqCC) (based on tumour positive cells in immunostainings). In a recent study, VEGF-A and Ang-2 were explored in NSCLC \[46\]. Both AC and SqCC expressed higher levels of VEGF-A and Ang-2 compared to paired-normal tissues. Positive associations between VEGF-A or Ang-2 and tumour size and lymph node metastasis were exclusively observed in AC and not in SqCC. Finally, another meta-analysis based on 30 NSCLC studies reported that HIF-1α expression was higher in the presence of lymph node metastasis (OR = 3.72; \(p < 0.0001\)), poor degrees of differentiation (OR = 2.12; \(p < 0.0001\)), or SqCC histology in comparison to AC (OR = 1.28; \(p = 0.03\)) \[47\]. In the same meta-analysis, additional expressions of hypoxia-related markers such as VEGF or CA-IX were assessed, with similar results to HIF-1α. Hypoxic features were also associated with higher tumoural microvessel density \[48,49\]. Although additional data are needed, several reports focused on HIF-2α expression in NSCLC with similar associations to HIF-1α \[50\]. Hypoxia could thus support carcinogenesis and tumour progression in the two histological sub-types involving distinct molecular pathways \[51–53\], ultimately leading to differential hypoxic-adaptation between AC and SqCC. Such carcinogenesis mechanisms could be supported by tumour-initiating cells.

2.2. Tumour-Initiating Cells and Hypoxic Conditions

2.2.1. Cancer Stem Cells Are Influenced by Hypoxia

Evidence is growing that some tumour cells harbour and retain a tumour-initiating cell phenotype involved in tumourigenesis or therapeutic resistance \[38,54,55\]. Interestingly, such CSC were preferentially observed in hypoxic areas, named niches, and both HIF-1α and HIF-2α were associated with induction and/or maintenance of CSCs across many cancer types including lung cancer \[56\]. CSC emerged as a promising model for cancer kinetic analysis from tumour initiation to invasion and metastasis \[57\]. Hypoxic-condition cultures of human primary lung cancer cells resulted in an enrichment of CSC harbouring aggressive and invasiveness features \[58\], suggesting selective pressure induced by hypoxia. Furthermore, hypoxia demonstrated its capacity to induce CSC properties, potentially supported by CXCR4 (C-X-C motif chemokine receptor 4) activation \[59\]. Invasion and metastatic properties can also be promoted by hypoxia through CSC stimulation \[60\]. Additionally, hypoxia-conditioned CSCs were associated with lower responses to therapies and poorer prognosis \[61\].

2.2.2. Epithelial to Mesenchymal Polarization by Hypoxia

Well in line with the observations that hypoxia enhances metastatic properties in various cancers and with important overlaps between EMT (epithelial–mesenchymal transition) and CSC features, a close relationship between EMT and hypoxic condition was also established, including mutual cell signalling pathways \[62\] or epigenetic regulations \[63\]. In the context of lung cancer, mesenchymal markers such as vimentin, and EMT transcription factors such as TWIST1 (Twist family BHLH transcription factor 1) or Snail were found overexpressed in hypoxic lung specimens while epithelial markers such as E-cadherin were repressed compared to non-hypoxic samples \[64–69\]. Such close relationships between EMT and hypoxia could thus be involved in aggressive phenotypes and resistance sustained by mesenchymal polarization \[70–72\]. Considering more frequent hypoxic features in mesenchymal tumours and higher aggressiveness and metastatic properties allocated to
non-epithelial specimens, hypoxia appears as an important mechanism supporting therapy resistance such as chemoresistance in hypoxic tumours. Interestingly, hypoxia-induced features such as EMT appear reversible, offering opportunities for drug development targeting hypoxic related-mechanisms [60,73,74].

2.3. Tumour Microenvironment Features in Hypoxic Condition

Along with the establishment of histological sub-types, additional phenotypical and immuno-histological observations are essential to refine the clinical strategy. The hypoxic condition impacts the entire tumour microenvironment (TME), contributing to the complex interplays established between tumour cells and neighbouring populations [75].

2.3.1. Hypoxia-Driven Stroma Modifications

Hypoxia impacts cancer-associated fibroblasts (CAF), immune cells, endothelial cells [76,77], or mesenchymal stem cells (MSCs) [78]. MSCs preconditioned via oxygen deprivation stimulated EMT which resulted in both enhanced properties of aggressiveness for tumour cells and M2 polarization of tumour-associated macrophages [79]. Exosomes, corresponding to 30–150 nm extracellular vesicles from the endosomal compartment, appeared to be largely involved in the molecular mechanisms of this intercellular dialogue between tumour cells and their distant microenvironment, as they could carry various sub-cellular information such as proteins, nucleic acids, or metabolites [78,80–83]. Hypoxia-activated host cells or hypoxia-driven stroma modifications were shown to sustain tumour cell aggressiveness and CSC/EMT features [84]. Moreover, hypoxia-induced tumour microenvironment morphological and biological modifications are associated with drug resistance and could also represent potential and promising aspects to target [85–88].

2.3.2. Inflammation Landscape in the Hypoxic Context

Hypoxia has proven to be a crucial regulator of inflammation and of many immune cell functions that are key targets of therapeutic strategies aiming at either restoring and/or activating anti-tumour immunity. Important crosstalk and bidirectional induction between HIFs and NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), a potent inducer of inflammation, were thus reported in various cancers including NSCLC [89].

Immune cells of the tumour microenvironment also play a crucial role in cancer development and immune response through tumour-associated macrophages (TAMs) or tumour-infiltrating lymphocytes (TILs) [90,91]. TAMs, representing most of the leukocyte population in the TME of solid malignancies, particularly mediate pro and/or anti-neoplastic effects dependent on macrophage polarization [92]. More particularly, they enhance tumour hypoxia and aerobic glycolysis in NSCLC both in pre-clinical and clinical contexts [93]. TAM depletion by clodronate was shown to reduce tumour hypoxia and increase intra-tumoural T-cell infiltrations, restoring efficacy to immune checkpoint inhibitor (ICI) [94]. The interactions between TAMs and hypoxia seem particularly promising and original therapeutic approaches are in development [95]. Moreover, hypoxia strongly impacts TILs in lung cancer [96]. A prognostic determinant 8-gene signature, based on TILs and cell oxygen sensing in 2712 tumours (including 515 NSCLC), was identified [97]. These reports are consistent with other markers and cohorts that establish positive correlations between hypoxic markers and TILs profusion and quiescence [98–101], highlighting a strong contribution of hypoxia in tumoural and peri-tumoural immune features.

2.3.3. Immune Checkpoint Disruption by Hypoxia

Hypoxia was also shown to induce PD-L1 expression to orchestrate cancer immune escape [102–104]. Immunotherapies and ICI such as anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) or anti-programmed death-ligand 1/programmed death-1 (PD-L1/PD-1) provided a significant improvement in NSCLC management [105]. Anti-PD-L1 interact preferentially with PD-L1 at the surface of immune cells to restore the anti-tumoural immune
response [106]. A significant correlation between PD-L1 and HIF-1α, VEGF-1 and CA-IX restricted to AC was reported in a cohort of 295 NSCLC [104].

2.4. Molecular Signature of Hypoxic Tumours

Additional and complemental consequences driven by hypoxia can be observed in NSCLC tumours, including metabolic reprogramming, especially with aerobic glycolysis upregulation, exosome biogenesis and secretion, neo-angiogenesis, lymphangiogenesis, or reactive oxygen species (ROS) production [84–86]. The molecular modifications serve as readouts of the cellular hypoxia-induced alterations.

2.4.1. Metabolic Consequences of Hypoxia

Aerobic glycolysis has been described as an adaptive mechanism of tumour growth in hypoxic conditions [107]. This persistent metabolism to lactate from glucose acidifies the peritumoural microenvironment and induces subpopulation cell resistance with enhanced division, and growth capacity. Interestingly, lung cancer cells and their microenvironment were investigated at the level of the cellular metabolisms such as lactate or pyruvate dehydrogenases (LDH and PDK, respectively), glucose transporters (GLUT), and HIF-1α/2α. In this comparative metabolic profile, cancer cells exhibited anaerobic features with higher GLUT capacities or lactate extrusion while TAMs presented a complementary profile with aerobic implications and lactate oxidation [108]. This report described a close interplay between the tumour and its peritumoural environment, especially regarding aerobic glycolysis, and highlighted additional molecular targets to evaluate hypoxia-induced cellular alterations.

2.4.2. Hypoxia Widely Impairs Cancer Gene Expression

High-throughput multi-omic approaches established the genetic prints of tumour hypoxia, introducing both complexities and clinical relevance to consider hypoxia in cancer. An impaired non-supervised pan-cancer core-metabolic gene signature was strongly associated with hypoxia in most common types of cancer [109]. Many pan-cancer (including NSCLC) hypoxia-associated gene expression signatures have been published and associated with a poor outcome [110–114].

2.4.3. Hypoxia Supports Molecular Alterations

A finely-tuned understanding of cancer biomolecular alterations led to major improvements for patient management as illustrated by the targeting of EGFR (epidermal growth factor receptor) alterations or ALK (anaplastic lymphoma kinase)/ROS1 (ROS proto-oncogene 1) rearrangements in NSCLC [115]. Hypoxia might be involved in the incidence of these molecular alterations: it was associated with high genomic instability and somatic genomic changes in a cancer report of 19 various tumour types. Hypoxic tumours exhibited characteristic driver-mutation signatures [116] and higher tumour mutational load with higher frequencies of driver mutations in PTEN (phosphatase and TENSins homolog), MYC (MYC proto-oncogene, BHLH transcription factor) and TP53 (tumour protein p53) [117]. Despite a few controversies, molecular polymorphisms have been extensively explored and HIF [118,119] or VEGF [120,121] polymorphisms have been associated with poor prognosis.

2.4.4. EGFR and ALK Genes Are More Frequently Altered in Hypoxic NSCLC Tumours

EGFR is an established activator of the HIF pathway, contributing to tumour progression. Data are also consistent with antiangiogenic effects in EGFR-TKIs in addition to proapoptotic activity. Hypoxia is proposed as a mechanism of resistance to anti-EGFR therapies that could be reversed [122–126]. For example, Yuan et al. explored associations between angiogenesis-inducible factor expressions and the presence of EGFR and KRAS (Kirsten ras oncogene homolog) mutations to specify the relationship between oncogenic alterations and hypoxia [127]. EGFR mutations concerning 21 or 20 exons (p = 0.002) were
associated with significantly high levels of VEGF-A. In contrast, tumours harbouring an exon 19 mutated EGFR exhibited lower levels of VEGFR1 (vascular endothelial growth factor receptor 1). KRAS mutations were also positively associated with VEGF/VEGFRs expression. Molecular cooperation between HIF-1α and c-Jun (c-Jun proto-oncogene) was described in NSCLC tumours harbouring an activating mutation of EGFR, resulting in both primary and acquired resistance to EGFR-TKI [128]. In another model, NSCLC cell lines with EGFR alterations (including T790M mutation, sensitizing to Osimertinib) were exposed to Osimertinib with a chronic and moderate hypoxic atmosphere. Interestingly, hypoxic NSCLC cell lines developed a resistance associated with a mesenchymal polarization and supported by FGFR1 (fibroblast growth factor receptor 1), largely resulting from mitogen-activated protein kinases (MAPK) pathway activation [129].

To summarise, hypoxia, and its cellular and molecular alterations, orchestrates hallmarks of lung cancer progression and metastasis such as CSC induction and maintenance, EMT, TME remodelling, immune escape, or oncogenic driver acquisition. This suggests a potentially promising clinical relevance for hypoxia characterisation in NSCLC. Figure 1 summarises cyto-histological features observed in hypoxic NSCLC tumours during lung carcinogenesis. There are currently two main limitations to integrating hypoxia status in real-time lung cancer management. Firstly, hypoxia can induce heterogeneous effects [130] after acute or chronic exposure. Cyclic levels of oxygen contribute to the hypoxia-induced cellular and molecular alterations [131]. Second, hypoxic markers rely on pathological examination and are limited due to tumour heterogeneity [132–134] and re-biopsy feasibility [135].
3. Available Tools to Detect Hypoxia in Clinical Practice

Innovative approaches are needed to tackle current clinical challenges in lung cancer management and to overcome current drawbacks. Clinicians appeal for easy-to-use robust markers to overcome tumour heterogeneity, stage cancer disease, detect metastasis, and predict patient outcomes during and after treatment. Thus, we review here alternative non-invasive methods evaluating hypoxia in NSCLC, and we highlight their potential relevance to help clinicians identify hypoxic tumours. These complementary approaches are depicted in Figure 2. Table 1 focuses on hypoxia-related markers with potential clinical relevance, considering their interest and respective limitations at meeting clinicians’ expectations.
Figure 2. Molecular, cellular, and whole-organism techniques to assess hypoxic status in lung cancer. Various methods to define hypoxic features are currently available or in development to meet clinician’s expectation.

Table 1. Hypoxia-related markers with a clinical interest in non-small cell lung cancer. HIF-1α: hypoxia-inducible. Figure 1. alpha, OS: overall survival, HIF-2α: hypoxia-inducible factor-2 alpha, Ang-2: angiopoietin-2, GLUT-1: glucose transporter-1, CA-IX: carbonic anhydrase-IX, OPN: osteopontin, VEGF: vascular endothelial growth factor, bFGF: basic fibroblast growth factor, CCL20: C-C motif chemokine ligand 20, CORO1C: coronin-1C, CTSC: cathepsin C, LDHA: lactate deshydrogenase A, NDRG: N-Myc downstream regulated 1, PTP4A3: protein tyrosine phosphatase 4A3, TUBA1B: tubulin alpha.

| Hypoxic Marker | Biological Material | Method of Assessment | Observation | Clinical Interest | Advantage | Limitation | Patients (n) | REF |
|----------------|---------------------|----------------------|-------------|-------------------|-----------|------------|-------------|-----|
| HIF-1 α        | Tumour cells        | Histological         | ↑ expression associated with lymph node metastasis | Staging     | Reproducible | Variability on HIF-1α threshold of positivity and its intracellular localization | 1436 [38] |
|                |                     |                      | ↑ expression associated with ↓ OS | Prognosis   |           |            | 1049 [38]  |
|                |                     |                      | ↓ serum concentration during chemoradiotherapy course | Response monitoring | Reproducible | Mini-invasive procedure Real-time monitoring | 1113 [47] |
|                | Serum concentrations| Circulating blood marker | ↓ expression associated with ↑ stages | Staging     | Reproducible | Restricted to stages I to III No association with HIF-1 α expression | 256 [136] |
| HIF-2 α        | Tumour cells        | Histological         | ↑ expression associated with ↑ stages | Staging     | Reproducible | No control group | 80 [137] |
|                |                     |                      | ↑ expression associated with ↓ OS | Prognosis   |           |            | 140 [50]  |
| Hypoxic Marker | Biological Material | Method of Assessment | Observation | Clinical Interest | Advantage | Limitation | Patients (n) | REF |
|----------------|---------------------|----------------------|-------------|-------------------|-----------|-----------|-------------|-----|
| Ang-2          | Tumour cells        | Histological and mRNA expression | ↑ expression associated with ↑ stages | Staging | Reproducible | mRNA expression not currently transposable in clinical routine | 1244 | [46] |
|                | Serum concentration | Circulating blood marker | ↑ concentration associated with ↑ stages | Diagnosis | Mini-invasive procedure | High threshold | 228 | [43] |
| GLUT-1         | Tumour cells        | Protein and mRNA expression | Co-expression with PD-L1 ↓ co-expression associated with ↑ OS | Prognosis | Reproducible | No evaluation of ICI sensibility | 295 | [104] |
| CA-IX          | Serum concentration | Circulating blood marker | ↑ concentrations associated with ↓ survival rates under radiotherapy | Prognosis | Mini-invasive procedure | Small effective | 55 | [138] |
| Flow extraction product | CT radiomic analysis | CT features | ↓ enhancement associated with lymph node metastasis Correlation with GLUT expression | Staging | Radiometabolic hypoxia-related markers | Small effective | 14 | [139] |
| Standardised Uptake Values (SUV) | PET radiomic analysis | Metabolic features | Correlation with histological HIF-1α expression | Not established | Non-invasive procedure | Non-investigation on prognosis | 288 | [140] |
| OPN            | Serum concentration | Circulating blood marker | ↑ concentrations associated with ↓ OS | Predictive of outcomes with chemoradiotherapy Predictive of outcomes with radiotherapy Predictive of tumoural response and prognosis with chemoradiotherapy | Non-invasive procedure | Included in a multiparametric model with other proteins | 263 | [141] |
| VEGF           | Tumour cells        | Histological and mRNA expression | ↑ concentration associated with ↓ OS | Monitoring of tumoural response under chemoradiotherapy | Reproducible | Variability on VEGF threshold of positivity and intracellular localization | 1549 | [145] |
|                | Serum concentration | Circulating blood marker | ↑ concentration associated with ↓ OS | Predictive of response and prognosis with immunotherapy | Non-invasive procedure | Significance restricted to elderly (>75 y.o) or PS > 2. | 235 | [146] |
|                |                      |                      | ↑ concentration associated with ↓ survival rates under radiotherapy | Predictive of outcomes with radiotherapy | Non-invasive procedure | Small effective | 55 | [138] |
### Table 1. Cont.

| Hypoxic Marker | Biological Material | Method of Assessment | Observation | Clinical Interest | Advantage | Limitation | Patients (n) | REF |
|----------------|---------------------|----------------------|-------------|-------------------|-----------|-----------|-------------|-----|
| bFGF           | Serum concentration | Circulating blood marker | ↑ concentration associated with ↓ OS | Monitoring of tumoural response under chemoradiotherapy regimen | Non-invasive procedure Tumour heterogeneity consideration Reproducible Real-time monitoring | Variability on bFGF threshold of positivity | 358 | [147] |
| miR-21, miR-128, miR-155, miR-181a | mi-RNA serum concentration | Circulating blood marker | Prediction of outcomes with first-line chemotherapy | Predictive of tumoural response Prognosis | Non-invasive procedure Reproducible Real-time monitoring | Not currently transposable in clinical routine Significance restricted to SqCC subgroup | 128 | [148] |
| CA-IX, CCL20, CORO1C, CTSC, LDHA, NDRG, PTP4A3, TUBA1B | Gene expression signature | mRNA expression | Predictive of hypoxic tumours associated with ↓ OS Co-expression with TILs infiltration | Prognosis | Non-invasive procedure Reproducible Real-time monitoring | Not currently transposable in clinical routine | 515 | [97] |

### 3.1. Hypoxic Characterisation by Imaging Techniques

Various non-invasive methods are available for clinicians to assess hypoxia in solid cancer cases. Lung cancer management currently involves contrast-enhanced computed tomography (CT) and positron emission tomography (PET) and could provide insight into hypoxic features. Other options include ultrasound imagery and magnetic resonance imaging which have been employed in clinical studies and might be relevant to assess hypoxia, especially in head and neck carcinoma [149–151]. However, they are not currently employed in lung cancer and hardly transposable for thoracic malignancy.

#### 3.1.1. Using Radiomics on Computed Tomography Images to Identify Hypoxic Tumours

CT is usually the first modality of imaging implemented in lung cancer management to establish a preliminary endo-thoracic staging. The emergence of radiomics in oncology unveiled the potential to analyse and quantify sub-visual features of CT images such as texture, wavelet, structure, and intensity to correlate with pathological characteristics [152]. Radiomics consists of the automatically high throughput extraction of a large amount of quantitative data from CT acquisitions and establishing models which predict biopathological features through a non-invasive approach [153]. A study by Ganeshan et al. sought to assess hypoxia by radiomics in 14 patients who underwent lung cancer surgery after intravenous injection of pimonidazole, a pathological hypoxia-related marker [154]. Pathological findings and image acquisition were then matched and compared. Two radiomic parameters (standard deviation of all pixel values and mean value of positive pixels) demonstrated the value of texture parameters. They correlated with hypoxic- and angiogenesis-related features observed by pathologists (i.e., angiogenesis explored by CD34 expression or pimonidazole staining). Other CT parameters based on enhancement after contrast injection, such as blood volume and flow-extraction products, also correlated with hypoxic histological findings in surgically resected NSCLC cohorts [139,155]. Additionally, radiomics and radiogenomics may help classify tumours based on their hypoxia status: radiomic features analysed with artificial intelligence were correlated with tumour hypoxia and further distinguished hypoxic area inside tumour heterogeneity [156]. CT texture analysis is confronted with non-standardised methods of acquisition, and further research is needed to establish guidelines [157] despite interesting results reported in NSCLC management.
3.1.2. Positive Emission Tomography Radiotracers Identify Hypoxia

Image acquisition by PET (based on cell metabolism activity) might be a promising non-invasive modality to better characterise hypoxia in NSCLC. Many PET tracers have been designed to identify the differential between hypoxic regions within tumours. They are mainly engineered based on a 2-nitroimidazole structure including $^{18}$F-HX4 (3-$^{18}$F]fluoro-2-(4-(2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-propan-1-ol) or $^{18}$F-FAZA (1-(5-$^{18}$F]fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole) [158]. The specific features for each radiotracer are not discussed here. Among them, $^{18}$F-MISO ($^{18}$F-fluoromisonidazole) has been identified as a robust marker of hypoxia [159,160] with good reproducibility [161] and validity [162–164], highlighting $^{18}$F-MISO as a potential hypoxia-relevant biomarker, especially in radiation management [165]. $^{18}$F-HX4 PET imaging also seems promising to document hypoxia in NSCLC [166–168]. $^{18}$F-HX4 and $^{18}$F-MISO successfully identified hypoxic areas within patient tumours four hours after intravenous injection. Interestingly, $^{18}$F-HX4 may emerge as the best option since it presents a higher contrast than $^{18}$F-MISO [169,170]. Additional radiotracers have been tested in preclinical and clinical models of NSCLC [166–168,171] but will not be discussed here.

3.1.3. Conventional $^{18}$F-FDG PET to Explore Hypoxia

Specific hypoxia radiotracers are expensive and currently not available in clinical routine. So far, PET imaging employs tracers composed of $^{18}$F-fluorodeoxyglucose (FDG), allowing clinicians to stage tumoural disease and identify potential lymph nodes and visceral metastasis [172]. Hypoxic examination by $^{18}$F-FDG PET has also been explored in NSCLC. A robust positive correlation between standardised uptake values (SUV) derived from $^{18}$F-FDG and HIF-1α expression based on three studies including 288 patients was addressed in a meta-analysis (pooled correlation of 0.42; $p = 0.02$). Additionally, five reports based on 310 patients identified a positive correlation between SUV and microvessel density [140]. $^{18}$F-FDG uptake and hypoxia association ($r = 0.54; p < 0.0001$) were also concordant with other reports exploring different approaches. A genetic signature associated with SUV intensity in NSCLC and largely consistent with hypoxia sensing was described and validated [173]. Since CD68 TAMs in the tumoural microenvironment are influenced by hypoxia, $^{18}$F-FDG PET has demonstrated its capacity to predict hypoxia in vivo with a positive correlation between SUV and CD68 positive staining, as reported in 98 matched NSCLC specimens [94].

3.1.4. Current Limitations for Hypoxia Characterisation by PET

Whether $^{18}$F-FDG and $^{18}$F-MISO can be useful, to characterise hypoxia requires additional investigations to assess their complementarity and limits. The efficiency of PET radiotracers to identify hypoxia could be evaluated on the tumour-muscle ratio in the same post-injection time lapse in the same population. However, comparisons are difficult in the absence of standardised methods. Other parameters such as tumour-to-blood ratios might be promising in hypoxic region determination [168]. Different kinetics and uptake profiles were obtained in a comparison of 34 non-resectable NSCLC hypermetabolic and hypoxic volumes, investigated by $^{18}$F-FDG and $^{18}$F-MISO [174]. To date, $^{18}$F-FDG PET based on SUV is used in daily clinical practice to determine malignancy probability before histologic confirmation or to perform a whole-body staging. As previously exposed, standard SUV acquisition by $^{18}$F-FDG PET alone appears insufficient to characterise hypoxic tumour regions with mismatch between metabolic and hypoxic regions. Other hypoxic-related radiotracers are thus needed and their addition to $^{18}$F-FDG tracer could be interesting. However, novel hypoxic-tracers’ validity, reproducibility, specificity, and standardisation represent the main current limitations for hypoxic investigation by PET.

In terms of accuracy, PET radiotracers are promising as non-invasive procedures. The $^{18}$F-HX4 tracer seems the most promising in the hypoxia field but the signal-to-noise ratio requires improvement [175]. Larger cohorts are needed to establish clinical relevance, by confronting various PET-acquired parameters with pathologically-matched hypoxia
features and association with prognostics. All in all, hypoxia imaging by PET acquisition offers many advantages beyond its non-invasive interest. Complementary radiotracers can be simultaneously used to explore patient tumour features [176]. Their associations could overcome current limits to their daily use in clinical management. Combining such non-invasive approaches could improve the clinical relevance of PET/CT imaging as illustrated by the growing interest for radiomic analyses of PET in NSCLC [177] or multimodal imaging to concomitantly assess perfusion, metabolism and hypoxia [178]. Although PET and CT are appealing procedures with a strong potential to evaluate hypoxia in patient tumours, their implementation in a reasonable real-time monitoring procedure is subjected to the availability of equipment, costs, and radiation exposition. [18F]-HX4 has appeared as the most promising tracer but clinical validation of alternative candidates is required to establish experimental guidelines (i.e., perfusion, acquisition parameters, etc.). Multimodal characterisation broadly based on blood-derived cancer products could overcome PET-associated drawbacks.

3.2. Circulating Markers to Help Clinicians Classify Hypoxic Tumours

Blood markers appear as a promising approach to meet clinical expectations. They avoid iterative radiation exposition, and technical bias induced by various methods of acquisition and analysis. Blood analysis is standardised, presents very low inter-operator biases, and reports circulating parameters that adapt therapeutics in a real-time manner. Several biomarkers that are assessable in blood could be of interest in the context of hypoxia: namely soluble protein, and derived tumour products such as tumour circulating DNA, circulating tumour cells, or circulating exosomes.

3.2.1. Soluble Blood Proteins Are Promising for the Identification of Hypoxic Tumours

So far, hypoxia investigations have focused mainly on serum blood biomarkers assessment. In a lung cancer cohort enrolling 263 non-metastatic and non-operable NSCLC treated by radiotherapy alone or with chemotherapy, high OPN and CA-IX serum concentrations (two blood markers related to the hypoxia pathway) were identified as negatively impacting overall survival (OS) [141]. The prognostic impact of various serum hypoxia-related proteins, such as OPN, CA-IX, and VEGF, was evaluated in a pilot study of 55 non-metastatic NSCLC undergoing radical radiotherapy [138]. They all correlated with clinical parameters associated with OS and a combined consideration of expression for those three markers was independently associated with poor outcome. Validation was then obtained in larger NSCLC cohorts, especially focused on OPN plasma levels [142,143,179]. HIF-1α serum levels in 80 patients harbouring NSCLC and undergoing chemoradiotherapy in a curative intent were assessed [137]: soluble HIF-1α levels were decreased during and after treatment compared to the initial point, suggesting serum HIF-1α concentrations as a potential marker to monitor tumour response during chemoradiation. Other soluble hypoxia-related biomarkers were assessed in patient serum with NSCLC including VEGF and basic fibroblast growth factor (bFGF): similar results were reported with poorer survival rates among patients with high serum concentrations of circulating VEGF and bFGF [147]. Despite interesting results that predict poor clinical outcomes for numerous hypoxia-related soluble markers, and their potential for the monitoring and management of lung cancer patients, a validation in larger cohorts is needed to prospectively confirm their clinical relevance and provide guidelines on blood measurements. Available reports were restricted to NSCLC treated by radiation, and other treatment modalities require exploration.

3.2.2. Tumour Circulating DNA/RNA Provide Hypoxia-Related Signatures

Tumour-released circulating DNA detection was recently implemented in the clinical practice of NSCLC, especially in the field of oncogenic drivers [180]. The interrelation between circulating tumour products and hypoxia condition was investigated. Hypoxia was associated with an increase of both circulating tumour DNA and tumour growth
in a model of mice grafted with lung cancer cell lines and exposed to intermittent hypoxia [181,182]. Circulating miRNA levels, a sub-group of small non-coding RNAs mainly repressing post-transcriptional gene expression, were also investigated in the context of hypoxia. Depending on the tumoural context, including hypoxia [183], they exerted both pro and/or anti oncogenic properties. Circulating miRNA (miR)-21, miR-128, miR-155, and miR-181a were quantified in 128 NSCLC cases undergoing first-line platinum-based chemotherapy treatment [148]. Higher expressions of miRNA levels were associated with worse survival. Integrated pathway analysis highlighted significant hypoxia-signalling involvement in miRNA targets. miRNAs present a great potential both as biomarkers and as a therapeutic strategy. However, their molecular and cellular mechanisms are not completely elucidated, and their assessment requires standardisation.

3.2.3. Circulating Tumour Cells Associated with Hypoxic Tumours

Among other tumour-circulating products, CTCs are reported in solid cancers but are still not currently used in clinical management [184]. In vitro evidence suggesting an interplay between hypoxia and CTC is growing. For instance, tumour-harbouring mesenchymal traits were characterised by EMT induction and mesenchymal polarisation in hypoxic conditions concomitant with an increased CTC count [36]. Additionally, hypoxia-inducing cancer stem cells and tumour growth might be associated with the emergence of CTCs [84]. In clinical conditions, CTCs were used to discriminate hypoxic status in metastatic breast cancers based on their HIF-1α and VEGF expressions with potential relevance [185]. Although CTCs were already used in NSCLC to assess features such as PD-L1 expression and/or EMT [186,187], no reports on hypoxia characterisation are currently available in lung cancer.

3.3. Emerging Approaches in Hypoxic-Tumour Identification

Circulating tumour DNA methylation might represent a promising and innovative approach to identifying markers able to deal with different challenges in the cancer field such as prediction of cancer risk [188]. Oxygen deprivation broadly impacts histone methylation in various types of cancer, including NSCLC [189–191] and cancer stem cells [59]. These epigenetic DNA modifications are clearly described in hypoxic conditions [192,193] and additional molecular targets are explored such as collagen 1A1 (COL1A1), RNA-binding and pre-mRNA processing factor 40 homolog A (PRPF40A) or uncoupling protein 2 (UCP2) [194,195]. The methylation status of over 1800 genes was altered in hypoxic conditions in cases of lung adenocarcinoma. Pathway enrichment analysis identified a large involvement in metabolic signalling, angiogenesis and cancer progression with a special interest for FAM20C (family with sequence similarity 20, member C), MYLIP (myosin regulatory light chain interacting protein), and COL7A1 (collagen type VII alpha 1 chain) predicting worsening outcomes for patients [196]. A close relationship between hypoxia (based on HIF-1α expression) and EGLN2 (Egl nine homolog 2) methylation was observed in lung adenocarcinoma and SqCC (n = 1230). EGLN2 methylation was associated with hypoxic features while the association of HIF-1α and EGLN2 enabled the identification of patients with poorer OS [197]. Other targets linked to hypoxia such as Cdkn2a (cyclin-dependent kinase inhibitor 2A) or Vdac1 (voltage-dependent anion-selective channel 1) [198,199] were identified in an innovative approach aiming to explore novel biomarkers for lung cancer in exhaled breath [200,201].

Innovative imaging procedures are also in development. The partial elucidation of the spatio-temporal signature of oxygen deprivation introduced an essential component of hypoxia. Experimental investigations are required to understand the impact of cyclic hypoxia in cancer genesis and progression [131]. The distribution and severity of hypoxia evaluated by the quantitative geographic monitoring of oxygen concentrations could bring additional relevant information to break current clinical limitations and modify therapy outcomes [202]. Other approaches such as metabolomics or proteomic analysis could
represent interesting techniques [111,203–206]. Such emerging technologies offer wide perspectives, but they require validation regarding their contribution to hypoxia.

4. Prognostic Implications of Hypoxia in Lung Cancer

NSCLC presents specific challenges depending on its stage of development. Locally advanced NSCLC, mostly represented by stages III of the IASLC classification, can still be cured but requires robust predictors of response to radiotherapy and chemoradiotherapy. Locally advanced stages share a mutual challenge, based on markers that can predict recurrence risk and outcome after curative treatment. Unfortunately, metastatic conditions remain common, and treatments sequentially based on chemotherapies, immunotherapies, and targeted therapies would also benefit from additional biomarkers capable of predicting tumour response.

4.1. Early and Locally Advanced Stages

4.1.1. Hypoxia Is Associated with Higher Tumour Stages

Accurate staging is a cornerstone in lung cancer management. Visceral metastasis detection leads to no-curative intent while lymph node metastases impose a more aggressive strategy combining (neo-)adjuvant therapies. Current NSCLC staging largely relies on imaging and mainly on PET/CT acquisition, which remains a transversal acquisition. Hypoxia could complement clinical staging and bring additional informative data on patient staging.

HIF-1α potential as a marker to identify patients with lymph node metastasis was investigated. Concordant with the association between HIF-1α expression and lymph node metastasis, high mRNA HIF-1α expression was also associated with tumour size and pathological stage \( (p < 0.05) \) [207]. HIF-1-induced products such as VEGF-A were also positively associated with larger tumour size, presence of lymph node metastasis, and more advanced pathological stages [48,49,208]. Additionally, other VEGFs proteins related to lymphangiogenesis such as VEGF-C were also positively associated with lymph node metastasis [209–212].

4.1.2. Hypoxia-Associated SNPs Revealed Higher Lung Cancer Risks

Single nucleotide polymorphisms (SNPs) present on genes related to hypoxia signalling, such as VEGF, were investigated as risk factors and potential markers of lung cancer susceptibility. Interestingly, VEGF SNPs rs833061 (−460T > C), rs2010963 (+405C > G), and rs3025039 (936C > T) were frequently reported with positive associations to lung cancer but restricted to sub-groups based on tumour histology [52,213] or gender [214,215]. These variable results were pooled and analysed in a meta-analysis of 13 studies including a total of 8823 patients (healthy volunteers and lung cancer patients) and no association was observed for VEGF SNP rs3025039, rs833061, and rs699947 (−2578C/A) with risk of lung cancer [216]. Controversially, a meta-analysis focusing on VEGF SNP rs699947 described lung cancer susceptibility in both the Asian and overall populations [217]. HIF-associated SNPs were also explored in lung cancer susceptibility. HIF-1α SNP rs11549465 was associated with overall cancer risk among 16,440 patients [119]. Regarding ethnicity, breast and lung cancer were higher in the Asian population while rs11549465 was associated with a protective effect against lung and breast cancer in the European population. Such controversies and variable observations need to be validated, due to the impact of ethnicity [219,220]. Concerning HIF-2α, Wang et al. conducted a non-supervised analysis of multi-omic NSCLC datasets in order to explore the potential association with lung cancer risk [111]. As expected, several members of the HIF gene family were at the centre of the molecular network and more interestingly, EPAS1 (also known as HIF-2α) SNP rs12614710 was associated with lung adenocarcinoma.
4.1.3. Hypoxia as a Prognostic Marker for Resected Tumours

Early NSCLC (represented by stages I and II) mostly benefit from surgical resections. Considering current guidelines, some sub-groups are eligible for post-operative chemotherapy based on platinum drugs despite a limited benefit on disease-free survival (DFS) and recurrence-free survival (RFS) rates [221]. The identification of biomarkers able to predict poorer outcomes after a surgical resection could distinguish specific patient sub-groups that could benefit from adjuvant therapies. Thus, hypoxia was assessed as a potential biomarker in the surgical context.

HIF-1α Expression Is Associated with Worse Clinical Outcomes

HIF-1α was associated with poor patient outcomes after surgical resection for head and neck SqCC [222]. Based on multi-histological types of solid cancer, a large meta-analysis assessed HIF-1 and HIF-2 impacts on clinical outcomes including OS, DFS, RFS, progression-free survival (PFS), and cancer-specific survival (CSS). HIF-1α was associated with poor global outcomes, including NSCLC with no association in SqCC. Similar results with higher HIF-1α expression were observed in another meta-analysis on 2056 patients (pooled HR = 1.80, p = 0.003) [38]. However, such a meta-analysis relies on various studies that are not all consistent. For example, the expression levels of HIF-1α were assessed in a cohort of 66 NSCLC who underwent surgical resection [223], where high HIF-1α expression was associated with poor outcomes, but exclusively in node-negative patients and not in patients with lymph node metastasis. As hypothesised, hypoxia might play an important role in tumour growth and progression but not in established late stages.

Hypoxia Related Prognosis and HIFs

Other hypoxia-related markers were investigated as companions to predict clinical outcomes. For example, CA-IX or VEGF-A expressions were proposed as independent poor prognosis factors for RFS and OS [64,224,225]. VEGF overexpression was also investigated in a pooled meta-analysis of 7631 patients and compared to the prognosis. High VEGF-A expression was an independent poor prognosis factor, regardless of the histological sub-types (HR = 1.775, 95%CI: 1.384–2.275 for AC and HR = 2.919, 95%CI: 2.060–4.137 for SCC) [226]. VEGFs SNPs as a predictor of clinical outcomes in NSCLC were also investigated. However, results were heterogeneous with distinct proposed SNPs and contradictory observations [52,121,227]. HIF-2α relevance as a prognostic marker was investigated in a large meta-analysis containing various solid tumours [228]. A strong association with HIF-2α overexpression and poor clinical outcomes such as OS (HR = 1.69, 95%CI: 1.39–2.06), DFS (HR = 1.87, 95%CI: 1.2–2.92), RFS (HR = 2.67, 95%CI: 1.32–5.38), and PFS (HR = 2.18, 95%CI: 1.25–3.78), including in NSCLC were reported. Finally, non-invasive methods were also investigated such as PET, using hypoxic-dedicated tracers [18F]-FAZA in a cohort of localised NSCLC [229,230]. Tumours with hypoxic radiological features were associated with poorer PFS and OS [173,230,231].

Different approaches and markers related to hypoxia are available and potentially useful to predict clinical prognosis. However, additional studies are needed to select the most robust and relevant companion markers among them.

4.1.4. Characterisation of Hypoxia to Improve the Clinical Course in Locally Advanced Stages

Current Strategy in Non-Resectable and Local NSCLC

About one-third of cases are diagnosed at a locally advanced stage, mostly only eligible to radiotherapy associated with platinum-based doublet chemotherapy and with poorer outcomes than surgically resectable tumours [232]. Clinical outcomes improved particularly with the use of durvalumab, an anti-PD-L1 immune blocker in maintenance. Nonetheless, the prognosis remained poor and many patients did not respond to radiotherapy and/or chemotherapy or developed major adverse-related events such as radiation-induced pneumonitis [233]. The need to identify markers able to predict clinical trajectories
and to adapt cancer management individually is highlighted. Different strategies were adopted to investigate the impact of hypoxia in locally advanced stages of NSCLC.

Hypoxic Features to Predict and Monitor Tumour Response

Hypoxic-related markers through $[^{18}\text{F}]$-MISO PET were assessed in 29 patients before their respective treatments [234]. Pre-therapeutic fractional hypoxic volume was thus associated with treatment response and PFS in an independent manner. Similar results were reported with $[^{18}\text{F}]$-FAZA PET [235] and VEGF SNP rs833061 [236]. Additionally, hypoxia-related markers were monitored during the course of chemoradiation. A decrease in HIF-1α serum level was observed in concurrence with tumour reduction and potentially predicted treatment response ($p < 0.001$) [137]. $[^{18}\text{F}]$-FAZA PET features at baseline were compared two and four weeks after treatment initiation and acquisition at the second week was proposed as the most relevant feature in the clinical management of NSCLC based on hypoxic parameters [237]. $[^{18}\text{F}]$-FAZA PET evolution at a later post-treatment end-point was assessed without significant correlations with DFS [235]. Beyond the prediction of treatment response, hypoxia was also proposed as a potential safety-marker in patients treated by radiotherapy [238–240]. VEGFs SNPs could be predictors of radiation pneumonitis while others could be protectors [241]. Hypoxia was also associated with a higher risk of treatment-related deaths in patients undertaking chemoradiation [239]. As previously reviewed, hypoxia characterisation from early to locally advanced stages might improve NSCLC detection, staging, and selection of the best clinical strategy to enhance patient outcomes. Although many results coincide, the most relevant approaches need to be characterised.

4.2. Metastatic Stages: Potential Hypoxia-Related Treatment Strategies, from Response to Resistance

Contrary to early and locally advanced stages, many patients with metastatic NSCLC are not entitled to curative treatments. The objectives of the therapeutic strategy are to reduce and/or stabilise both loco-regional and distant disease and to prevent additional metastatic sites that burden OS. Current approaches combine various regimens of chemotherapy, immunotherapy, and targeted therapy such as EGFR-TKIs. Assuming that hypoxia was the main factor and a key player interacting with the progress of metastasis [242], our study investigated how hypoxic characterisation could enhance lung cancer management through each clinical therapeutic option currently available. Higher tumour incidence and maintenance of CSC or metabolic adaptation in hypoxic conditions were reported, suggesting that hypoxia may act as a major driver of resistance [243–245], with potential differential effects related to HIF-1α [246] and HIF-2 [247].

4.2.1. Hypoxic Tumours Are Associated with a Higher Risk of Distant Metastasis

Considering distant visceral metastasis detection, hypoxia was broadly identified as a promoter of cancer growth and metastasis in various cancer types, including lung cancer [248]. More specifically, bone marrow metastasis, invasion, and colonisation were found associated with hypoxia [249]. HIF-1α expression in primary tumour tissues and the presence of bone metastasis was investigated in a retrospective cohort study of 96 patients with NSCLC [250]. Patients with bone metastasis harboured higher HIF-1α expression (in both intensity and tumour positive stained cell) than patients without bone metastasis. This positive association persisted in the adjusted analysis. The identification of tumour-harbouring hypoxic features could thus help clinicians evaluate the presence of bone marrow metastasis. These reports suggest that hypoxia (through HIF-1α or other related markers) could enhance NSCLC staging, both for lymph node and visceral metastasis.

4.2.2. Chemotherapy

Among different drugs currently indicated in NSCLC, the platinum-based doublet regimen remains the main combination used, especially in first or second-line. However, response rates do not exceed 40% in first [251–253] and 15% in second-line. Hypoxia was
investigated and proposed as a driver of chemoresistance in lung cancer [254]. A cohort of patients including 602 NSCLC treated by platinum-based regimen was genotyped on 42 genes involved in hypoxia sensing. Two variants (EXO1 (exonuclease 1) and RPA1 (replication protein A1)) were associated with worse response and clinical outcomes [255]. Complementarily, HIF-1α sequencing established a positive association between the presence of the 1772 CC genotype and higher response to platin salts and longer OS. In the same cohort, HIF-1α protein expression was a predictor of non-response to platinum-based chemotherapies [256]. Hypoxia was also evaluated in a non-invasive manner, by assessing VEGF serum level in patients treated with a first-line of carboplatin and paclitaxel at baseline and after two cycles of treatment. Whereas no significant changes in VEGF concentrations were noticed between the two-time points, responsive patients (including partial and stable disease) had lower levels of soluble VEGF than non-responders [257]. Other reports were consistent, based on lymphangiogenesis-related markers such as VEGF-C, VEGF-D, and soluble VEGF-R2 [258] or exploring other mono chemotherapy treatments employed in NSCLC such as paclitaxel or vinorelbine [259,260]. All those observations of hypoxic-driven chemoresistance in lung cancer are supported by preclinical reports and identified different actors, including direct involvement of HIF-1α, p53 mutation [261,262], CSC [263], YTHDF1 (YTH N6-methyladenosine RNA binding protein 1) [264], miR-128, and miR-155 [148]. Other non-specific mechanisms of resistance were described such as hypoxia-induced P-glycoprotein (p-Gp) [265] or epidermal growth factor-like domain 7, associated with multidrug resistance [266].

4.2.3. Immunotherapy

Current Use of Immune-Checkpoint Inhibitors

Immunotherapies with a monoclonal antibody targeting anti-PD-L1 as a spearhead rapidly emerged and were placed in first-line treatments [251]. However, combined or used alone, response rates do not exceed 50% and relapse fatally occurs. As previously reported, hypoxia affects histological immune features and the tumour microenvironment by ultimately converging to an immune escape.

Hypoxia as a Predictor of Response under ICI Regimens

PD-L1 and VEGF-A were significantly co-expressed in a cohort of 129 surgical specimens (p = 0.002, r = −0.274), suggesting a potential interplay between hypoxia and PD-L1. Moreover, co-expressing sub-groups were associated with worse PFS and OS than the control group (p = 0.005), unveiling a potential interest in also targeting this association in the early stages [267]. This was supported by both preclinical and clinical models [268–270]. Interestingly, radiomics features were used to characterise hypoxic status in a cohort of 59 NSCLC treated by nivolumab [231] where tumours with hypoxic features had poorer clinical outcomes with anti-PD-1 use than non-hypoxic tumours. Immune resistance mediated by hypoxia is supported by preclinical experiments involving notch-hedgehog signalling and CSCs [271] Interestingly, therapeutic oxygenation may reverse this immune resistance [272,273]. However, only a few studies have investigated immune responses considering tumour hypoxic characterisation [274–276].

4.2.4. Radiotherapy

Due to radiation-induced damage and its biological effects, hypoxia has been extensively investigated through radiation therapies in various solid cancers. PET imaging was mainly used for tumour hypoxic characterisation and enabled longitudinal monitoring during radiation [277].

Hypoxic Imaging to Guide Radiotherapy Strategies

Poor prognosis in patients with hypoxic tumours treated by radiotherapy was established across different radiation modalities [229,278–281]. It prompted to adapt, guide, and enhance radiotherapy intensity in hypoxic tumour sub-areas [282–286]. Thus, the RTEP-5
(radiotherapy dose complement in the treatment of hypoxic lesions) study experimented with a radiotherapy dose increase according to tumour-associated hypoxic features assessed by $[^{18}F]$-MISO PET in unresectable NSCLC. Despite high dose escalation up to 86 Gy, this trial did not meet its first primary endpoint, whereas local radiotherapy intensification seemed to improve OS in its updated content with more frequent radiation-related adverse events [287]. Radiotherapy based on hypoxic-imaging characterisation appears insufficient and additional biomarkers are needed.

### Biological Hypoxia-Related Markers Improving Radiotherapy Success

Several hypoxia gene signatures were developed as predictors of the radiotherapy response [142,288,289]. Radiation tumour resistance is complex [290] and involves many hypoxic elements such as HIF-1/2, ROS [291–294], heat shock proteins [295,296], or miR-210 complex [297,298]. They could emerge as promising hypoxia-related biomarkers to predict response and outcomes with radiotherapy, but clinical validation is required. Hypoxia-induced radio-resistance was modified by EGFR mutation status. EGFR mutant NSCLC cells were more sensitive to radiation than non-mutant cells which suggests a potentially relevant interplay between hypoxia and EGFR in NSCLC [299]. Hypoxic assessment as a guideline for radiotherapy strategies should be further evaluated alone or in combination with the genomic status or the immune profile.

#### 4.2.5. Targeted Therapies

**KRAS**

Kirsten rat sarcoma (KRAS) mutations remain the most common molecular alterations in NSCLC. Despite considerable efforts of investigation, this molecular pattern has only experimental therapies [300,301]. A COPD-like inflammation supported a tumourigenic effect of KRAS mutant lung cancer, driven by HIF-1α [302,303]. Additionally, KRAS mutant NSCLC secreted a specific cytokine profile with neutrophil recruitment into the tumour micro-environment, resulting in a pro-hypoxic condition [304]. HIF-1α inhibition (by Ras-PI3K-Akt pathway downregulation) in cell line models harbouring KRAS mutation repressed metastatic behaviour (proliferative and metastatic properties) [305]. Hypoxia consequences on KRAS mutant tumours have been investigated with other therapies. KRAS mutant cells were incubated with 3-bromopyruvate (3-BrPA), a promising alkylating metabolic inhibitor of cancer with KRAS mutation. While non-hypoxic cells exhibited a standard sensitivity, hypoxic conditions led to drug resistance for this molecule [306]. Thus, experimental data suggested that examining both KRAS molecular mutation and hypoxic status could have particular clinical significance. Considering the effectiveness of anti-KRAS therapies, selected patients with KRAS-mutant NSCLC harbouring non-hypoxic patterns could thus benefit from KRAS inhibitors.

**EGFR**

- **Current Clinical Application of anti-EGFR in NSCLC**

Several targeted therapies have been developed over the past decades to block activating EGFR mutations such as erlotinib, afatinib, and gefitinib. Those actionable mutations are observed in NSCLC sub-groups and represent about 10–15% of patients. Response rates and OS were drastically improved with these drugs. Osimertinib, an EGFR-TKI designed to overcome T790M—a common second mutation of resistance—is indicated and employed in first-line treatment. However, primary or secondary resistance inevitably occurs, and in many cases in the absence of additionally acquired mutations [307]. Interestingly, erlotinib is indicated in the global population and has demonstrated its efficacy in a non-mutated EGFR NSCLC population without an identified response or resistance-marker to date [308], highlighting EGFR-TKIs activity in non-mutant tumours, and the lack of relevant markers in this situation. We then reviewed the potential interest of defining hypoxia to improve EGFR-TKIs management, in both wild type (WT) and mutant EGFR NSCLC.

- **Hypoxia Could Predict Non-Response to EGFR TKIs in Wild-Type EGFR NSCLC**
In WT EGFR NSCLC, gefitinib and erlotinib treatment lead to a decrease in VEGF concentrations in tumour cells. This complex molecular mechanism involves HIF-1-dependent and independent pathways [309]. The interplay between EGFR resistance and hypoxia was investigated on NSCLC cells exposed to gefitinib and varying O2 levels. Interestingly, hypoxic NSCLC gefitinib-treated cells harboured greater resistance which was supported by IL-6 secretion and adaptive tumour inflammation [310]. Beyond EGFR mutation in a global population, HIF-1α expression was associated with poor outcomes, also supporting the need to consider a tandem for EGFR and hypoxia [311]. Moreover, 42 unselected patients with NSCLC were recruited in a pilot study to identify markers able to predict outcomes with combined anti-VEGF/anti-EGFR treatment in q WT-EGFR population. Gene expression profiling was performed before treatment with bevacizumab and erlotinib. Interestingly, gene set enrichment analysis identified hypoxia and angiogenesis-related signatures. Cluster analysis highlighted a hypoxia signature that distinguished two clusters based on prognosis. Patients with higher hypoxia-related gene expression were associated with lower response rates to combined therapies and poorer outcomes [312]. Both preclinical and clinical observations suggested that hypoxic features in EGFR-WT NSCLC could predict poor responses to EGFR-TKIs.

- **Hypoxia Led to EGFR TKIs Resistance in Mutant EGFR NSCLC**

  Hypoxia-induced Gefitinib resistance in EGFR-mutant specimens is broadly mediated by HIF-1α [313,314]. Hypoxia seemed to support various mechanisms of resistance. For example, 202 NSCLC specimens were screened for EGFR mutations where mutant EGFR tumours were found to harbour higher expressions of MET. This pattern constituted a bypass mechanism of resistance to EGFR-TKIs that was induced by HIF-1α [315,316]. Other mechanisms of resistance have been described, including the activation of insulin-like growth factor 1 receptor (IGFRI) [317], LSD-1 (lysine-specific histone demethylase 1) [318] or JUN [319]. Beyond first-line resistance to EGFR-TKIs, acquisition of T790M EGFR mutation is common. Higher HIF-1α gene expression in both chemo-resistant NSCLC and mesenchymal polarised tumours was observed [320]. In this context, HIF-1α overexpression led to EMT and chemoresistance while its inhibition restored chemosensitivity [321], highlighting a central role of hypoxia, even in tumours harbouring T790M mutation.

- **Promising Strategies to Overcome Hypoxia-Mediated Resistance with EGFR-TKIs**

  In NSCLC harbouring exon 19 EGFR deletions, the erlotinib-cisplatin combination allowed to inhibit both HIF-1α and VEGF pathways, and was associated with greater responses [322], suggesting a potential interest in mutant-EGFR NSCLC with a resistance to EGFR-TKIs supported by hypoxia. Furthermore, an interim analysis of a randomised phase 3 trial assessing erlotinib/bevacizumab vs. erlotinib in 228 patients with a mutant EGFR status was published recently. Despite inconclusive results, combination drugs significantly improved clinical outcomes compared to erlotinib alone (HR: 0.605, 95%CI 0.417–0.877; \(p = 0.016\)), suggesting clinical relevance in targeting hypoxia for the EGFR mutation context, [323] and further trials are ongoing [324–326].

**ALK**

ALK-TKIs such as crizotinib or alectinib were developed to counteract constitutive activation of ALK receptor, mostly mediated by activating ALK fusions such as ALK-EML4 [327]. Unfortunately, clinical course is still conditioned to primary and inevitable secondary resistance. As observed in EGFR and hypoxia interplay, data suggest a close relationship between those ALK alterations and hypoxic condition. It was even described that ALK directly controlled HIF concentrations in hypoxic conditions for NSCLC [328]. Resistance to ALK-TKIs can be mediated by various mechanisms [329] where hypoxic conditions might play a potential role [330]. Thus, a hypoxia-mediated resistance to crizotinib via EMT induction was reported [331]. Interestingly, this resistance was labile and reversible after hypoxic reversion or HIF-1α inhibition, highlighting the potential relevance to counteract hypoxia in ALK-rearranged tumours harbouring TKI resistances. However,
resistance to therapies involves many other factors such as PD-L1 overexpression mediated by HIF-1α in ALK-rearranged NSCLC specimens and promoting immune escape [332]. The development of hypoxia counteractors with ALK-related TKIs is a current challenge for future therapeutics [333].

5. Hypoxia-Related Treatments and Research Development

Current systemic approaches including chemotherapies, immunotherapies, TKIs, or radiotherapy are facing primary or secondary resistance where hypoxia can sustain a major role. As the tumour cancer cells and/or the tumour microenvironment may trigger hypoxia, several strategies have been designed to reverse its negative effects. In this section, we will review several therapeutic approaches targeting hypoxia: reduction of oxygen consumption, hypoxia-activated cytotoxic prodrugs, blockers of anaerobic metabolism, or anti-angiogenic molecules.

5.1. Pyruvate Dehydrogenase Kinase (PDK) Inhibitors

HIFs transcriptional complex largely interferes with glucose metabolism in hypoxic cells [334]. PDK genes are expressed and regulated by a HIF-associated transcription program via downregulation of mitochondrial oxygen consumption leading to a reduction of oxygen consumption [335]. PDK inhibitors have been designed to hijack this hypoxic tumour cell adaptation [336].

Among various PDK isoforms, PDK1 is featured as a key player in NSCLC metabolic adaptation [337]. Dichloroacetate (DCA) is a PDK1 inhibitor that was investigated in various solid cancers including NSCLC. Preclinical data on NSCLC cell lines were encouraging with anti-tumoural effect, synergistic with EGFR-TKIs (for erlotinib and gefitinib) [338], and overcome acquired-resistance to EGFR-TKIs [339]. However, no clinical trial was conducted in EGFR-mutant conditions to date. Excluding the EGFR-addiction context, DCA was tested in addition with 2-methoxyestradiol (2-ME), a metabolite reducing angiogenesis, replication, and HIF-1α pathway in human tumour cell-lines. The combination exhibited promising anti-tumour effects in preclinical A549 NSCLC cell lines [340]. Current clinical data available on DCA explored its anti-tumour properties in a phase II trial, including 6 patients with NSCLC (and 1 patient with breast cancer). Unfortunately, the clinical trial was closed regarding safety concerns after seven enrolments [341]. No additional trials are active concerning DCA, probably due to its worse tolerance profile.

The Cpd64 (2,2-Dichloro-1-(4-isopropoxy-3-nitrophenyl)ethan-1-one) was also proposed as a more specific and potent PDK1 inhibitor. It was tested in the human EGFR-mutant NSCLC cell line and demonstrated synergistic effects with erlotinib, especially by an increase of anti-proliferative effects under hypoxic conditions. In xenografts, Cpd64 increased the tumour growth inhibition in addition to erlotinib [342]. However, no clinical trial is investigating Cpd64 anti-tumour efficacity. Finally, PK-M2 appeared as specifically expressed in cancer cells and emerged as a promising target involved in the acquisition of metastatic and neoangiogenesis features [343–345]. However, no clinical data are currently available.

5.2. Metformin

Metformin, a well-known anti-diabetic drug has also been proposed as an anti-cancer treatment with immunogenic and anti-proliferative properties, inhibiting oxygen consumption by both adenosine monophosphate-activated protein kinase (AMPK) dependant and independent pathways [346]. Metformin was thus explored in a small effective trial of 15 patients treated by radiotherapy. Modification of tumour activity evaluated by PET was noticed while the small effective limited robust conclusions [347]. Other clinical trials observed promising activity with metformin administration in combination with ICI for various solid cancers, including NSCLC [348]. To date, only retrospective studies are available regarding metformin in NSCLC. For example, in a controlled cohort of 100 patients, improved clinical outcomes were reported (ORR and DCR at 41% ($p = 0.4$) and
70% (p = 0.5), respectively [349]. Another retrospective study of 166 patients treated by chemoradiotherapy reported a non-significant difference in combination with metformin [350]. Similar non-significant results were published in smaller cohorts [351,352]. A larger non-randomised retrospective study on nationwide prescription cohort proposed benefits associated with metformin co-administration in NSCLC patients [353]. Therefore, the administration of metformin in NSCLC is still under investigation (NCT02109549) and its place is being explored in various combinations such as immunotherapy (NCT02186847), or stereotaxic ablative radiation (NCT04170959), but not EGFR-TKI because of a negative randomised study of 224 patients with EGFR mutated NSCLC treated by gefitinib with or without metformin [354].

Other molecules influencing glucose metabolism in hypoxic conditions such as GLUT-1 were also explored. This HIF-1α partner has been mainly investigated as a prognostic marker in NSCLC [355]. Patient-derived xenograft models, NSCLC cell lines, primary human NSCLC cultures, and public Tumour Cancer Genome Atlas databases highlighted an important implication of GLUT-1 in NSCLC [356]. However, no clinical trial data are available in the context of lung cancer management.

5.3. Vorinostat

Vorinostat is a histone deacetylase (HDAC) inhibitor increasing HIF-1α degradation [357,358]. As its efficacy was insufficient in monotherapy [359–361], vorinostat was administered in a phase II randomised double-blind and placebo-controlled trial, associated with carboplatin/paclitaxel chemotherapy in 94 patients with NSCLC [362]. A response rate of 34% was observed in the vorinostat arm (vs. 12.5%, p = 0.02 in the placebo arm). The small effective did not permit to conclude on PFS and OS while a trend was observed in favour to vorinostat combination (6.0 months vs. 4.1 months and 13.0 months vs. 9.7 months, respectively). The safety profile remained manageable, mainly represented by grade 4 thrombopenia which occurred in 18% vs. 3% in the placebo arm. Concurrently with stereotactic radiosurgery, a phase I dose-escalation trial was also conducted to determine a maximum tolerated dose for vorinostat in monotherapy as a radiosensitiser in 14 NSCLC patients [363]. Although no dose-limiting toxicity was observed, five patients early withdrew the protocol, highlighting a labile clinical tolerance. Concerning EGFR mutation, a non-randomised phase I/II trial enrolled 33 NSCLC patients experiencing resistance to erlotinib. Vorinostat (400 mg/day) was added to erlotinib and PFS was evaluated at 12 weeks. Vorinostat was insufficient to reverse EGFR-TKI acquired resistance in EGFR mutant condition [364]. Similarly, vorinostat failed to improve PFS in combination with gefitinib in other clinical trials including patients with EGFR-mutant NSCLC [365,366]. ICI and particularly pembrolizumab combined with vorinostat (400 mg/day) was explored in a phase 1 study, including 33 patients with advanced NSCLC. No additional safety concerns were reported and a disease control rate of 67% was reported (including four (13%) partial response and 16 (53%) stable disease) [367]. Such promising preliminary results justified current recruitment for Pembrolizumab combined with vorinostat in metastatic NSCLC (NCT02638090).

5.4. Nitroglycerin

Nitroglycerin (NTG) is a vasodilator molecule that inhibits HIF-1α, resulting in tumour blood flow increase and reduced oxygen privation. Its addition, it was evaluated in combination with various chemotherapy regimen for patients with NSCLC. A randomised phase II trial enrolled 120 patients harbouring advanced NSCLC and evaluated the addition of NTG patches (25 mg daily for 5 days) to the vinorelbine/cisplatin chemotherapy regimen [368]. This trial was positive, with a response rate increased to 72% in the intervention NTG-arm vs. 42% in the control group. Both PFS and OF were significantly improved (adjusted HRPFS = 2.1, p = 0.002 and adjusted HROS = 2.5, p < 0.001 respectively). A randomised phase II trial enrolled 223 chemo-naïve patients with metastatic non-squamous NSCLC, comparing carboplatin-paclitaxel-bevacizumab with or without NTG patches
The safety profile was noticed while no improvement of PFS or OS was reported in favour of the NTG arm. Such discordance between the two trials might be attributed to the bevacizumab as an anti-angiogenic drug. Although side effects remained manageable (mainly represented by headache, commonly observed with vasodilator treatments), a dedicated phase III trial investigating NTG addition for 5 days with conventional first-line chemotherapy in advanced NSCLC patients was stopped at first interim analysis for non-significance [370]. Its combination with radiotherapy failed to demonstrate a clinical interest and no additional investigations are currently evaluated for this approach [371].

5.5. Tirapazamine

As a model of a specific hypoxia-related drug, tirapazamine is a synthetic molecule that is activated in hypoxic conditions to a toxic radical [372]. This drug was thus investigated in a randomised 1:1 phase III of 446 patients with NSCLC, in combination with cisplatin. Both OS and response rate were improved (34.6 vs. 27.7 weeks, \( p = 0.078 \) and 27.5 vs. 13.7, \( p < 0.001 \); respectively) [373]. Despite positive results supporting clinical relevance, the development of tirapazamine in NSCLC was stopped without integration in clinical lung cancer management (NCT00066742), and no results were published.

5.6. Efaproxiral

As a fibric acid derivative displacing oxygen from hemoglobin to hypoxic tissue ultimately leading to an increase of oxygen delivery, efaproxiral exhibited promising results in phase I/II but failed in the later phase of clinical development, especially as a radiosensitiser and hypoxic target therapies [374–376]. Several additional clinical trials are ongoing with novel radiosensitisers [377, 378], and modified radiotherapy protocols according to the hypoxic region to enhance immune cytogenic anti-cancer effect [379, 380].

5.7. Anti-Angiogenic Therapies

They are currently available in lung cancer including bevacizumab, a monoclonal anti-VEGF antibody [381]. Associated with an improvement in clinical outcomes, it remains restricted to sub-populations and excluded from regular cases such as SqCC, brain metastasis, or thrombotic history [382]. Despite the development of bevacizumab as a drug specifically targeting neoangiogenesis, no predictive markers for angiogenic inhibition are available. To date, bevacizumab is still indicated in combination with other treatments, especially chemotherapies [383]. Other anti-angiogenic drugs are mostly investigated in combination with other treatments such as immunotherapy or targeted therapy, based on potential synergistic efficacy [384].

More conventional anti-angiogenic therapies such as bevacizumab gain interest [385] and both clinical and preclinical data are cumulating for synergistic effects of angiogenic inhibition with ICI [386]. Dedicated clinical trials are ongoing, questioning the addition of anti-angiogenic treatment to immunotherapy and chemotherapy now widely used in the NSCLC first-line for pembrolizumab [387] or atezolizumab (NCT03836066, NCT03896074). Interestingly, lenvatinib (a multi-receptor TKI targeting VEGFRs and FGFRs) exhibited both safety and signal of activity in combination with pembrolizumab or chemotherapy in phases Ib/II [388, 389]. Several trials are ongoing for lenvatinib in combination with chemotherapies specifically in NSCLC (NCT03829332; NCT03829319; NCT04875585) and should provide their results in the coming years.

6. Conclusions

In this study, we conducted an extensive review of the potential impact of hypoxia in each stage of NSCLC and highlighted clinical and pathological features related to hypoxic tumours relevant to clinicians. It appears that some tumours are more frequently associated with hypoxic regions than others, such as poorly differentiated SqCC presenting a tumour microenvironment including high tumoural microvessel density and stroma-enriched im-
mune cells harbouring epithelial-to-mesenchymal polarisation. The current challenge to identifying hypoxia remains the definition of relevant thresholds for markers discriminating hypoxic from non-hypoxic tumours. Pathological examinations and immunostainings are needed to validate further markers in paired and matched comparison studies. The identification of biological signatures based on nucleic acid expressions may contribute to the development of hypoxic-scores after validation in larger and design-dedicated cohorts. Systematic genetic association studies taking hypoxia as a relevant parameter will ideally complement the translational approach. We also reviewed current promising approaches allowing to evaluate hypoxia in the NSCLC context with a special interest in the most suitable and transposable approaches in clinical routine. Tumour hypoxia biology is complex and in constant evolution over time, given that sequential drugs and radiation use lead to resistance and treatment escape. We finally investigated how hypoxic characterisation could influence the major steps of lung cancer clinical management. For patients with early cured NSCLC, transversal hypoxic tumour determination might also be of interest to isolate and predict those who would benefit from adjuvant therapies to reduce the risk of relapse. Nonetheless, challenges and clinical goals are specific in advanced and metastatic stages when aiming to predict tumour response across various regimens of treatments. In these later stages, longitudinal hypoxic characterisation might be the most relevant approach. Repeated PET/CT scans and more strikingly, circulating hypoxia-related markers may enable monitoring of tumour variations and adaptation of clinical strategies in a personalised approach. Despite limitations to hypoxia implementation in lung cancer clinical management, evidence is accumulating for its consideration, including dedicated hypoxia-related treatments. Hypoxia characterisation could improve the outcome of patients with NSCLC and might represent the next step to a personalised medical protocol in the field of cancer.

Author Contributions: Conceptualization, J.A.; formal analysis, J.A., J.-M.P., M.D., C.L., P.M., B.N.-R., V.D. (Véronique Dalstein), C.G., G.D., M.P. and V.D. (Valérian Dormoy); writing—original draft preparation, J.A. and V.D. (Valérian Dormoy); writing-review and editing, J.A., J.-M.P., G.D., M.P. and V.D. (Valérian Dormoy); supervision, G.D., M.P. and V.D. (Valérian Dormoy); funding acquisition, G.D., M.P. and V.D. (Valérian Dormoy). All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by funding from the University of Reims Champagne-Ardenne (URCA), the French National Institute of Health and Medical Research (Inserm).

Acknowledgments: The research effort associated with this article was funded in part by the «Partenariat Hubert Curien-Tournesol» and the Fonds de la Recherche Scientifique-FNRS (FRS-FNRS, Belgium). The authors thank Daniela Pellot (SERRA, Service of proofreading and support in English, University of Reims Champagne-Ardenne, France) for English language editing. The figures were created with BioRender.com (accessed on 23 June 2021).

Conflicts of Interest: G.D. reports personal fees from Nuvaira, personal fees from BTG/PneumRx, personal fees from Chiesi, personal fees from Boehringer, personal fees from Astra Zeneca, outside the submitted work. V.D. (Valérian Dormoy) reports personal fees from Chiesi outside the submitted work. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2018, 68, 394–424. [CrossRef]
2. Duma, N.; Santana-Davila, R.; Molina, J.R. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin. Proc. 2019, 94, 1623–1640. [CrossRef] [PubMed]
3. Reck, M.; Rabe, K.F. Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2017, 377, 849–861. [CrossRef] [PubMed]
4. Korpanty, G.J.; Graham, D.M.; Vincent, M.D.; Leighton, N.B. Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. Front. Oncol. 2014, 4, 204. [CrossRef]
5. Prelaj, A.; Tay, R.; Ferrara, R.; Chaput, N.; Besse, B.; Califano, R. Predictive Biomarkers of Response for Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer. *Eur. J. Cancer* 2019, 106, 144–159. [CrossRef]

6. Allemani, C.; Matsuda, T.; Di Carlo, V.; Harewood, R.; Matz, M.; Nikšić, M.; Bonaventure, A.; Valkov, M.; Johnson, C.J.; Estève, J.; et al. Global Surveillance of Trends in Cancer Survival 2000-14 (CONCORD-3): Analysis of Individual Records for 37 513 025 Patients Diagnosed with One of 18 Cancers from 322 Population-Based Registries in 71 Countries. *Lancet* 2018, 391, 1023–1075. [CrossRef]

7. Chen, P.-S.; Chiu, W.-T.; Hsu, P.-L.; Lin, S.-C.; Peng, I.-C.; Wang, C.-Y.; Tsai, S.-J. Pathophysiological Implications of Hypoxia in Human Diseases. *J. Biomed. Sci.* 2020, 27, 63. [CrossRef]

8. Mouronte-Roibal, C.; Leiro-Fernández, V.; Fernández-Villar, A.; Botana-Rial, M.; Ramos-Hernández, C.; Ruano-Ravina, A. COPD, Emphysema and the Onset of Lung Cancer. A Systematic Review. *Cancer Lett.* 2016, 382, 240–244. [CrossRef]

9. Semenza, G.L. Hypoxia-Inducible Factors in Physiology and Medicine. *Cancers* 2021, 13, 3421.
35. Balamurugan, K. HIF-1 at the Crossroads of Hypoxia, Inflammation, and Cancer. *Int. J. Cancer* 2016, 138, 1058–1066. [CrossRef] [PubMed]

36. Tirpe, A.A.; Gulei, D.; Ciortea, S.M.; Crivii, C.; Berindan-Neagoe, I. Hypoxia: Overview on Hypoxia-Mediated Mechanisms with a Focus on the Role of HIF Genes. *Int. J. Mol. Sci.* 2019, 20, 6140. [CrossRef] [PubMed]

37. Goudar, R.K.; Vlahovic, G. Hypoxia, Angiogenesis, and Lung Cancer. *Curr. Oncol. Rep.* 2008, 10, 277–282. [CrossRef] [PubMed]

38. Yang, S.-I.; Ren, Q.-G.; Wen, L.; Hu, J.-L. Clinicopathological and Prognostic Significance of Hypoxia-Inducible Factor-1 Alpha in Lung Cancer: A Systematic Review with Meta-Analysis. *J. Huazhong Univ. Sci. Technol. Med. Sci.* 2016, 36, 321–327. [CrossRef]

39. Xu, C.; Wang, W.; Wang, Y.; Zhang, X.; Yan, J.; Yu, L. Serum Angiopoietin-2 as a Clinical Marker for Lung Cancer in Patients with Histologic Type, Tumor Angiogenesis, Patient Survival and Timing of Relapse in Non-Small-Cell Lung Cancer. *Oncol. Rep.* 2019, 41, 667–682. [CrossRef] [PubMed]

40. Albadari, N.; Deng, S.; Li, W. The Transcriptional Factors HIF-1 and HIF-2 and Their Novel Inhibitors in Cancer Therapy. *Expert Opin. Drug Discov.* 2019, 14, 105–119. [CrossRef] [PubMed]

41. Xiong, Q.; Liu, B.; Ding, M.; Zhou, J.; Yang, C.; Chen, Y. Hypoxia and Cancer Related Pathology. *Cancer Lett.* 2020, 486, 1–7. [CrossRef]

42. Laddha, A.P.; Kulkarni, Y.A. VEGF and FGF-2: Promising Targets for the Treatment of Respiratory Disorders. *Respir. Med.* 2019, 156, 33–46. [CrossRef] [PubMed]

43. Yuan, A.; Yu, C.J.; Chen, W.J.; Lin, F.Y.; Kuo, S.H.; Luh, K.T.; Yang, P.C. Correlation of Total VEGF MRNA and Protein Expression with Histologic Type, Tumor Angiogenesis, Patient Survival and Timing of Relapse in Non-Small-Cell Lung Cancer. *Cancer Lett.* 2019, 486, 4744–4752. [CrossRef] [PubMed]

44. Albadari, N.; Deng, S.; Li, W. The Transcriptional Factors HIF-1 and HIF-2 and Their Novel Inhibitors in Cancer Therapy. *Expert Opin. Drug Discov.* 2019, 14, 667–682. [CrossRef] [PubMed]

45. Albadari, N.; Deng, S.; Li, W. The Transcriptional Factors HIF-1 and HIF-2 and Their Novel Inhibitors in Cancer Therapy. *Expert Opin. Drug Discov.* 2019, 14, 667–682. [CrossRef] [PubMed]

46. Qin, S.; Yi, M.; Jiao, D.; Li, A.; Wu, K. Distinct Roles of VEGFA and ANGPT2 in Lung Adenocarcinoma and Squamous Cell Carcinoma. *J. Cancer* 2020, 11, 156–167. [CrossRef] [PubMed]

47. Ren, W.; Mi, D.; Yang, K.; Cao, N.; Tian, J.; Li, Z.; Ma, B. The Expression of Hypoxia-Inducible Factor-1α and Its Clinical Significance in Lung Cancer: A Systematic Review and Meta-Analysis. *Swiss Med. Wkly.* 2013, 143, w13855. [CrossRef]

48. Liu, J.; Liu, Y.; Gong, W.; Kong, X.; Wang, C.; Wang, S.; Liu, L. The Role of Serum Angiopoietin-2 Levels in Progression and Prognosis of Lung Cancer: A Meta-Analysis. *Medicine* 2017, 96, e8063. [CrossRef] [PubMed]

49. Tirpe, A.A.; Gulei, D.; Ciortea, S.M.; Crivii, C.; Berindan-Neagoe, I. Hypoxia: Overview on Hypoxia-Mediated Mechanisms with a Focus on the Role of HIF Genes. *Int. J. Mol. Sci.* 2019, 20, 6140. [CrossRef] [PubMed]

50. Balamurugan, K. HIF-1 at the Crossroads of Hypoxia, Inflammation, and Cancer. *Int. J. Cancer* 2016, 138, 1058–1066. [CrossRef] [PubMed]

51. Bajaj, J.; Diaz, E.; Reya, T. Stem Cells in Cancer Initiation and Progression. *J. Cell Biol.* 2020, 209. [CrossRef] [PubMed]

52. Lee, S.; Kang, H.G.; Choi, J.E.; Lee, J.H.; Kang, H.J.; Baek, S.A.; Lee, E.; Seok, Y.; Lee, W.K.; Lee, S.Y.; et al. The Different Effect of VEGF Polymorphisms on the Prognosis of Non-Small Cell Lung Cancer According to Tumor Histology. *Cancer Sci.* 2016, 107, 4729–4736. [CrossRef]

53. Tirpe, A.A.; Gulei, D.; Ciortea, S.M.; Crivii, C.; Berindan-Neagoe, I. Hypoxia: Overview on Hypoxia-Mediated Mechanisms with a Focus on the Role of HIF Genes. *Int. J. Mol. Sci.* 2019, 20, 6140. [CrossRef] [PubMed]

54. Albadari, N.; Deng, S.; Li, W. The Transcriptional Factors HIF-1 and HIF-2 and Their Novel Inhibitors in Cancer Therapy. *Expert Opin. Drug Discov.* 2019, 14, 667–682. [CrossRef] [PubMed]

55. Albadari, N.; Deng, S.; Li, W. The Transcriptional Factors HIF-1 and HIF-2 and Their Novel Inhibitors in Cancer Therapy. *Expert Opin. Drug Discov.* 2019, 14, 667–682. [CrossRef] [PubMed]

56. Tong, W.-W.; Tong, G.-H.; Liu, Y. Cancer Stem Cells and Hypoxia-Inducible Factors (Review). *Tumor Hypoxia.* 2019, 100, 1366–1373. [CrossRef] [PubMed]

57. Bajaj, J.; Diaz, E.; Reya, T. Stem Cells in Cancer Initiation and Progression. *J. Cell Biol.* 2020, 209. [CrossRef] [PubMed]

58. Saforo, D.; Omer, L.; Smolenkov, A.; Barve, A.; Casson, L.; Boyd, N.; Clark, G.; Siskind, L.; Beverly, L. Primary Lung Cancer Samples Cultured under Microenvironment-Mimetic Conditions Enrich for Mesenchymal Stem-like Cells That Promote Metastasis. *Sci. Rep.* 2019, 9, 4177. [CrossRef] [PubMed]

59. Albadari, N.; Deng, S.; Li, W. The Transcriptional Factors HIF-1 and HIF-2 and Their Novel Inhibitors in Cancer Therapy. *Expert Opin. Drug Discov.* 2019, 14, 667–682. [CrossRef] [PubMed]

60. Chen, J.; Xu, R.; Xia, J.; Huang, J.; Su, B.; Wang, S. Aspirin Inhibits Hypoxia-Mediated Lung Cancer Cell Stemness and Exosome Function. *Pathol. Res. Pract.* 2019, 215, 152379. [CrossRef] [PubMed]

61. Zhao, M.; Zhang, Y.; Zhang, H.; Wang, S.; Zhang, M.; Chen, X.; Wang, H.; Zeng, G.; Chen, X.; Liu, G.; et al. Hypoxia-Induced Cell Stemness Leads to Drug Resistance and Poor Prognosis in Lung Adenocarcinoma. *Lung Cancer* 2015, 87, 98–106. [CrossRef] [PubMed]

62. Tam, S.Y.; Wu, V.W.C.; Law, H.K.W. Hypoxia-Induced Epithelial-Mesenchymal Transition in Cancers: HIF-1α and Beyond. *Front. Oncol.* 2020, 10, 486. [CrossRef] [PubMed]
63. Yeo, C.D.; Kang, N.; Choi, S.Y.; Kim, B.N.; Park, C.K.; Kim, J.W.; Kim, Y.K.; Kim, S.J. The Role of Hypoxia on the Acquisition of Epithelial-Mesenchymal Transition and Cancer Stemness: A Possible Link to Epigenetic Regulation. *Korean J. Intern. Med*. 2017, 32, 589–599. [CrossRef] [PubMed]

64. Emprou, C.; Le Van Quyen, P.; Jégou, J.; Prim, N.; Weingertner, N.; Guérin, E.; Pencreach, E.; Legrain, M.; Voegeli, A.-C.; Ledue, C.; et al. SNAI2 and TWIST1 in Lymph Node Progression in Early Stages of NSCLC Patients. *Cancer Med.* 2018. [CrossRef]

65. Wei, L.; Sun, J.-J.; Cui, Y.-C.; Jiang, S.-L.; Wang, X.-W.; Lv, L.-Y.; Xie, L.; Song, X.-R. Twist May Be Associated with Invasion and Metastasis of Hypoxic NSCLC Cells. *Tumour Biol.* 2016, 37, 9979–9987. [CrossRef] [PubMed]

66. Hung, J.-J.; Yang, M.-H.; Hsu, H.-S.; Hsu, W.-H.; Liu, J.-S.; Wu, K.-J. Prognostic Significance of Hypoxia-Inducible Factor-1alpha, TWIST1 and Small Expression in Recesetble Non-Small Cell Lung Cancer. *Thorax* 2009, 64, 1082–1089. [CrossRef]

67. Zhang, J.; Wang, J.; Xing, H.; Li, Q.; Zhao, Q.; Li, J. Down-Regulation of FB1 by ZEB1-Mediated Repression Confers to Growth and Invasion in Lung Cancer Cells. *Mol. Cell. Biochem.* 2016, 411, 331–340. [CrossRef]

68. Ruan, J.; Zhang, L.; Yan, L.; Liu, Y.; Yue, Z.; Chen, L.; Wang, A.-Y.; Chen, W.; Zheng, S.; Wang, S.; et al. Inhibition of Hypoxia-Induced Epithelial Mesenchymal Transition by Luteolin in Non-Small Cell Lung Cancer Cells. *Mol. Med. Rep.* 2012, 6, 232–238. [CrossRef]

69. Kong, X.; Zhao, Y.; Li, X.; Tao, Z.; Hou, M.; Ma, H. Overexpression of HIF-2α-Dependent NEAT1 Promotes the Progression of Non-Small Cell Lung Cancer through MiR-101-3p/SOX9/Wnt/β-Catenin Signal Pathway. *Cell. Physiol. Biochem.* 2019, 52, 368–381. [CrossRef]

70. Liu, X.; Chen, H.; Xu, X.; Ye, M.; Cao, H.; Xu, L.; Hou, Y.; Tang, J.; Zhou, D.; Bai, Y.; et al. Insulin-like Growth Factor-1 Receptor Knockdown Enhances Radiosensitivity via the HIF-1α Pathway and Attenuates ATM/H2AX/53BPI DNA Repair Activation in Human Lung Squamous Carcinoma Cells. *OncoL. Lett.* 2018, 16, 1332–1340. [CrossRef]

71. Kim, I.-G.; Lee, J.-H.; Kim, S.-Y.; Hwang, H.-M.; Kim, T.-R.; Cho, E.-W. Hypoxia-Inducible Transgelin 2 Selects Epithelial-to-Mesenchymal Transition and γ-Radiation-Resistant Subtypes by Focal Adhesion Kinase-Associated Insulin-like Growth Factor 1 Receptor Activation in Non-Small-Cell Lung Cancer Cells. *Cancer Sci.* 2018, 109, 3519–3531. [CrossRef] [PubMed]

72. Nurwidya, F.; Takahashi, F.; Kobayashi, I.; Murakami, A.; Kato, M.; Minakata, K.; Nara, T.; Hashimoto, M.; Yagishita, S.; Baskoro, H.; et al. Treatment with Insulin-like Growth Factor 1 Receptor Inhibitor Reverses Hypoxia-Induced Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer. *Biocem. Biophys. Res. Commun.* 2014, 453, 332–338. [CrossRef]

73. Wang, J.; Tian, L.; Khan, M.N.; Zhang, L.; Chen, Q.; Zhao, Y.; Yan, Q.; Fu, L.; Liu, J. Ginsenoside Rg3 Sensitizes Hypoxic Lung Cancer Cells to Cisplatin via Blocking of NF-κB Mediated Epithelial-Mesenchymal Transition and Stemness. *Cancer Lett.* 2018, 415, 73–85. [CrossRef]

74. Wu, C.-E.; Zhuang, Y.-W.; Zhou, J.-Y.; Liu, S.-L.; Dou, C.; Wang, R.-P.; Shu, P. Nm23-H1 Inhibits Hypoxia Induced Epithelial-Mesenchymal Transition and Stemness in Non-Small Cell Lung Cancer Cells. *Biol. Chem.* 2019, 400, 765–776. [CrossRef]

75. Tan, S.; Xia, L.; Yi, P.; Han, Y.; Tang, L.; Pan, Q.; Tian, Y.; Rao, S.; Oyang, L.; Liang, J.; et al. Exosomal MiRNAs in Tumor Microenvironment. *J. Exp. Clin. Cancer Res.* 2020, 39, 67. [CrossRef] [PubMed]

76. Laitala, A.; Erler, J.T. Hypoxia Signalling in Tumour Stroma. *Front. Oncol.* 2018, 8, 189. [CrossRef] [PubMed]

77. Farina, A.R.; Cappabianca, L.; Sebastiano, M.; Zelli, V.; Guadagni, S.; Mackay, A.R. Hypoxia-Induced Alternative Splicing: The 11th Hallmark of Cancer. *J. Exp. Clin. Cancer Res.* 2020, 39, 110. [CrossRef] [PubMed]

78. Zhang, X.; Sai, B.; Wang, F.; Wang, L.; Wang, Y.; Zheng, L.; Li, G.; Tang, J.; Xiang, J. Hypoxic BMSC-Derived Exosomal MiRNAs Promote Metastasis of Lung Cancer Cells via STAT3-Induced EMT. *Mol. Cancer* 2019, 18, 40. [CrossRef] [PubMed]

79. Ren, W.; Hou, J.; Yang, C.; Wang, H.; Hu, S.; Wu, Y.; Zhao, X.; Lu, E. Extracellular Vesicles Secreted by Hypoxia Pre-Challenged Mesenchymal Stem Cells Promote Non-Small Cell Lung Cancer Cell Growth and Mobility as Well as Macrophage M2 Polarization via MiR-21-5p Delivery. *J. Exp. Clin. Cancer Res.* 2019, 38, 62. [CrossRef]

80. Kao, S.-H.; Cheng, W.-C.; Wang, Y.-T.; Wu, H.-T.; Yeh, H.-Y.; Chen, Y.-J.; Tsai, M.-H.; Wu, K.-J. Regulation of MiRNA Biogenesis and Histone Modification by K63-Polyubiquitinated DDX17 Controls Cancer Stem-like Features. *Cancers* 2019, 79, 2549–2563. [CrossRef]

81. Chen, X.; Wu, L.; Li, D.; Xu, Y.; Zhang, L.; Niu, K.; Kong, R.; Gu, J.; Xu, Z.; Chen, Z.; et al. Radiosensitizing Effects of MiR-18a-5p on Lung Cancer Stem-like Cells via Downregulating Both ATM and HIF-1α. *Cancer Med.* 2018, 7, 3834–3847. [CrossRef] [PubMed]

82. Kumar, A.; Deep, G. Exosomes in Hypoxia-Induced Remodeling of the Tumor Microenvironment. *Cancer Lett.* 2020, 488, 1–8. [CrossRef]

83. Jafari, R.; Rabbarghazi, R.; Ahmadi, M.; Hassanpour, M.; Rezaie, J. Hypoxia Exosomes Orchestrate Tumorigenesis: Molecular Mechanisms and Therapeutic Implications. *J. Transl. Med.* 2020, 18, 474. [CrossRef]

84. Noman, M.Z.; Messai, Y.; Muret, J.; Hasmim, M.; Chouaib, S. Crossstalk between CTC, Immune System and Hypoxic Tumor Microenvironment. *Cancer Microenviron.* 2014, 7, 153–160. [CrossRef]

85. Wang, B.; Zhao, Q.; Zhang, Y.; Liu, Z.; Zheng, Z.; Liu, S.; Meng, L.; Xin, Y.; Jiang, X. Targeting Hypoxia in the Tumor Microenvironment: A Potential Strategy to Improve Cancer Immunotherapy. *J. Exp. Clin. Cancer Res.* 2021, 40, 24. [CrossRef]

86. Hajizadeh, F.; Oyoei, I.; Esmaily, M.; Ghasemi Chaleshtari, M.; Masjedi, A.; Azizi, G.; Irandoust, M.; Ghalamfar, G.; Jadidi-Niaragh, F. Hypoxia Inducible Factors in the Tumor Microenvironment as Therapeutic Targets of Cancer Stem Cells. *Life Sci.* 2019, 237, 116952. [CrossRef] [PubMed]

87. Giannone, G.; Ghisoni, E.; Genta, S.; Scotto, G.; Tuninetti, V.; Turinneto, M.; Valabrega, G. Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy. *Int. J. Mol. Sci.* 2020, 21, 4414. [CrossRef]
88. Mittal, V.; El Rayes, T.; Narula, N.; McGraw, T.E.; Altorki, N.K.; Barcellos-Hoff, M.H. The Microenvironment of Lung Cancer and Therapeutic Implications. *Adv. Exp. Med. Biol.* **2016**, *890*, 75–110. [CrossRef]

89. D’Ignazio, L.; Batie, M.; Rocha, S. Hypoxia and Inflammation in Cancer, Focus on HIF and NF-KB. *Biomedicines* **2017**, *5*, 21. [CrossRef]

90. Cassetta, L.; Kitamura, T. Macrophage Targeting: Opening New Possibilities for Cancer Immunotherapy. *Immunology* **2018**, *155*, 285–293. [CrossRef]

91. Bremnes, R.M.; Busund, L.-T.; Kilvær, T.L.; Andersen, S.; Richardsen, E.; Paulsen, E.E.; Hald, S.; Khanehkani, M.R.; Cooper, W.A.; Kao, S.C.; et al. The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small-Cell Lung Cancer. *J. Thorac. Oncol.* **2016**, *11*, 789–800. [CrossRef]

92. Henze, A.-T.; Mazzone, M. The Impact of Hypoxia on Tumor-Associated Macrophages. *J. Clin. Investig.* **2016**, *126*, 3672–3679. [CrossRef] [PubMed]

93. Poh, A.R.; Ernst, M. Targeting Macrophages in Cancer: From Bench to Bedside. *Front. Oncol.* **2018**, *8*, 49. [CrossRef]

94. Jeong, H.; Kim, S.; Hong, B.-J.; Lee, C.-J.; Kim, Y.-E.; Bok, S.; Oh, J.-M.; Gwak, S.-H.; Yoo, M.Y.; Lee, M.S.; et al. Tumor-Associated Macrophages Enhance Tumor Hypoxia and Aerobic Glycolysis. *Cancer Res.* **2019**, *79*, 795–806. [CrossRef] [PubMed]

95. Silva, V.L.; Al-Jamal, W.T. Exploiting the Cancer Niche: Tumor-Associated Macrophages and Hypoxia as Promising Synergistic Targets for Nano-Based Therapy. *J. Control. Release* **2017**, *253*, 82–96. [CrossRef] [PubMed]

96. Noël, G.; Langouo Fontsa, M.; Willard-Gallo, K. The Impact of Tumor Cell Metabolism on T Cell-Mediated Immune Responses and Immuno-Metabolic Biomarkers in Cancer. *Semin. Cancer Biol.* **2018**, *52*, 66–74. [CrossRef] [PubMed]

97. Chang, W.H.; Forde, D.; Lai, A.G. A Novel Signature Derived from Immunoregulatory and Hypoxia Genes Predicts Prognosis in Liver and Five Other Cancers. *J. Transl. Med.* **2019**, *17*, 14. [CrossRef] [PubMed]

98. Giatromanolaki, A.; Harris, A.L.; Banham, A.H.; Contralouris, C.A.; Koukourakis, M.I. Carbonic Anhydrase 9 (CA9) Expression in Non-Small-Cell Lung Cancer: Correlation with Regulatory FOXP3+T-Cell Tumour Stroma Infiltration. *Br. J. Cancer* **2020**, *122*, 1205–1210. [CrossRef]

99. Akbarpour, M.; Khalyfa, A.; Qiao, Z.; Gileles-Hillel, A.; Almendros, I.; Farré, R.; Gozal, D. Altered CD8+ T-Cell Lymphocyte Function and TC1 Cell Stemness Contribute to Enhanced Malignant Tumor Properties in Murine Models of Sleep Apnea. *Sleep* **2017**, *40*. [CrossRef] [PubMed]

100. Noman, M.Z.; Buart, S.; Romero, P.; Ketari, S.; Janji, B.; Mari, B.; Mami-Chouaib, F.; Chouaib, S. Hypoxia-Inducible MiR-210 Regulates the Susceptibility of Tumor Cells to Lysis by Cytotoxic T Cells. *Cancer Res.* **2012**, *72*, 4629–4641. [CrossRef] [PubMed]

101. Noman, M.Z.; Janji, B.; Kaminska, B.; Van Moer, K.; Przanowski, P.; Buart, S.; Berchem, G.; Romero, P.; Mami-Chouaib, F.; et al. Blocking Hypoxia-Induced Autophagy in Tumors Restores Cytotoxic T-Cell Activity and Promotes Regression. *Cancer Res.* **2011**, *71*, 5976–5986. [CrossRef]

102. Dong, Z.-Y.; Wu, S.-P.; Liao, R.-Q.; Huang, S.-M.; Wu, Y.-L. Potential Biomarker for Checkpoint Blockade Immunotherapy and Treatment Strategy. *Tumour Biol.* **2016**, *37*, 4251–4261. [CrossRef]

103. Giatromanolaki, A.; Koukourakis, I.M.; Balaska, K.; Mitrakas, A.G.; Harris, A.L.; Koukourakis, M.I. Programmed Death-1 Receptor (PD-1) and PD-Ligand-1 (PD-L1) Expression in Non-Small Cell Lung Cancer and the Immune-Suppressive Effect of Anaerobic Glycolysis. *Med. Oncol.* **2019**, *36*, 76. [CrossRef]

104. Koh, Y.W.; Lee, S.J.; Han, J.-H.; Haam, S.; Jung, J.; Lee, H.W. PD-L1 Protein Expression in Non-Small-Cell Lung Cancer and Its Relationship with the Hypoxia-Related Signaling Pathways: A Study Based on Immunohistochemistry and RNA Sequencing Data. *Lung Cancer* **2019**, *129*, 41–47. [CrossRef]

105. Corrales, L.; Scilla, K.; Caglevic, C.; Miller, K.; Oliveira, J.; Rolfo, C. Immunotherapy in Lung Cancer: A New Age in Cancer Treatment. *Adv. Exp. Med. Biol.* **2018**, *995*, 65–95. [CrossRef] [PubMed]

106. Sharpe, A.H.; Pauken, K.E. The Diverse Functions of the PD1 Inhibitory Pathway. *Nat. Rev. Immunol.* **2018**, *18*, 153–167. [CrossRef] [PubMed]

107. Gatesby, R.A.; Gillies, R.J. Why Do Cancers Have High Aerobic Glycolysis? *Nat. Rev. Cancer* **2004**, *4*, 891–899. [CrossRef] [PubMed]

108. Koukourakis, M.I.; Giatromanolaki, A.; Bougioukas, G.; Sivridis, E. Lung Cancer: A Comparative Study of Metabolism Related Protein Expression in Cancer Cells and Tumor Associated Stroma. *Cancer Biol. Ther.* **2007**, *6*, 1476–1479. [CrossRef] [PubMed]

109. Haider, S.; McIntyre, A.; van Stiphout, R.G.P.M.; Winchester, L.M.; Wigfield, S.; Harris, A.L.; Buffa, F.M. Genomic Alterations Underlie a Pan-Cancer Metabolic Shift Associated with Tumour Hypoxia. *Genome Biol.* **2016**, *17*, 140. [CrossRef]

110. Chang, W.H.; Lai, A.G. Transcriptional Landscape of DNA Repair Genes Underpins a Pan-Cancer Prognostic Signature Associated with Cell Cycle Dysregulation and Tumor Hypoxia. *DNA Repair* **2019**, *78*, 142–153. [CrossRef]

111. Wang, Z.; Wei, Y.; Zhang, R.; Su, L.; Gogarten, S.M.; Liu, G.; Brennan, P.; Field, J.K.; McKay, J.D.; Lissowska, J.; et al. Multi-Omics Analysis Reveals a HIF Network and Hub Gene EPAS1 Associated with Lung Adenocarcinoma. *EBioMedicine* **2018**, *32*, 93–101. [CrossRef]

112. Harris, B.H.L.; Barberis, A.; West, C.M.L.; Buffa, F.M. Gene Expression Signatures as Biomarkers of Tumour Hypoxia. *Clin. Oncol.* **2015**, *27*, 547–560. [CrossRef]

113. Buffa, F.M.; Harris, A.L.; West, C.M.; Miller, C.J. Large Meta-Analysis of Multiple Cancers Reveals a Common, Compact and Highly Prognostic Hypoxia Metagene. *Br. J. Cancer* **2010**, *102*, 428–435. [CrossRef]
114. Chen, Y.-L.; Zhang, Y.; Wang, J.; Chen, N.; Fang, W.; Zhong, J.; Liu, Y.; Qin, R.; Yu, X.; Sun, Z.; et al. A 17 Gene Panel for Non-Small-Cell Lung Cancer Prognosis Identified through Integrative Epigenomic-Transcriptomic Analyses of Hypoxia-Induced Epithelial-Mesenchymal Transition. *Mol. Oncol.* 2019, 13, 1490–1502. [CrossRef]

115. Ferrara, M.G.; Di Noia, V.; D’Argento, E.; Vita, E.; Damiano, P.; Cannella, A.; Ribelli, M.; Pilotto, S.; Milella, M.; Tortora, G.; et al. Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives. *Cancers* 2020, 12, 1196. [CrossRef] [PubMed]

116. Bhandari, V.; Hoey, C.; Liu, L.Y.; Lalonde, E.; Ray, J.; Livingstone, J.; Lesurf, R.; Shiah, Y.-J.; Vujcic, T.; Huang, X.; et al. Molecular Landmarks of Tumor Hypoxia across Cancer Types. *Nat. Genet.* 2019, 51, 308–318. [CrossRef]

117. Bhandari, V.; Li, C.H.; Bristow, R.G.; Boutros, P.C. PCAWG Consortium Divergent Mutational Processes Distinguish Hypoxic and Normoxic Tumours. *Nat. Commun.* 2020, 11, 737. [CrossRef]

118. Hu, X.; Fang, Y.; Zheng, J.; He, Y.; Zan, X.; Lin, S.; Li, X.; Li, H.; You, C. The Association between HIF-1α Polymorphism and Cancer Risk: A Systematic Review and Meta-Analysis. *Tumour Biol.* 2014, 35, 903–916. [CrossRef]

119. Li, Y.; Li, C.; Lou, L.; Liu, P. The Association between the Rs11549465 Polymorphism in the Hif-1α Promoter and Epstein–Barr Virus Infection with Nasopharyngeal Carcinoma. *Int. J. Clin. Exp. Med.* 2015, 8, 1561–1574.

120. Jain, L.; Vargo, C.A.; Danesi, R.; Sissung, T.M.; Price, D.K.; Venzon, D.; Venitz, J.; Figg, W.D. The Role of Vascular Endothelial Growth Factor SNPs as Predictive and Prognostic Markers for Major Solid Tumors. *Mol. Cancer Ther.* 2009, 8, 2496–2508. [CrossRef]

121. Heist, R.S.; Zhai, R.; Liu, G.; Zhou, W.; Lin, X.; Su, L.; Asomaning, K.; Lynch, T.J.; Wain, J.C.; Christiani, D.C. VEGF Polymorphisms and Survival in Early-Stage Non-Small-Cell Lung Cancer. *J. Clin. Oncol.* 2008, 26, 856–862. [CrossRef]

122. Wouters, A.; Boeckx, C.; Vermorken, J.B.; Van den Weyngaert, D.; Peeters, M.; Lardon, F. The Intriguing Interplay between Hypoxia and Epidermal Growth Factor Receptor in Non-Small-Cell Lung Cancer. *Radiother. Oncol.* 2013, 19, 907–917. [CrossRef]

123. Qi, H.; Wang, S.; Wu, J.; Yang, S.; Gray, S.; Ng, C.S.H.; Du, J.; Underwood, M.J.; Li, M.-Y.; Chen, G.G. EGFR-AS1/HIF2A Regulates Hypoxia Increases the Motility of Lung Adenocarcinoma Cell Line A549 via Activation of the Epidermal Growth Factor Receptor Pathway. *Cancer Sci.* 2007, 98, 506–511. [CrossRef]

124. Bubendorf, L.; et al. The Challenge of NSCLC Diagnosis and Predictive Analysis on Small Samples. Practical Approach of Molecular Markers and Immuno-histochemistry. *Biomarkers* 2004, 9, 435–441. [CrossRef] [PubMed]

125. Thunnissen, E.; Herth, F.J.; Lantuejoul, S.; Papotti, M.; Rintoul, R.C.; Rossi, G.; Skov, B.G.; Weynand, B.; Bubendorf, L.; et al. The Challenge of NSCLC Diagnosis and Predictive Analysis on Small Samples. Practical Approach of a Working Group. *Lung Cancer* 2012, 76, 1–18. [CrossRef]

126. Zheng, H.; Ning, Y.; Zhan, Y.; Liu, S.; Yang, Y.; Wen, Q.; Fan, S. Co-Expression of PD-L1 and HIF-1α Predicts Poor Prognosis in Patients with Non-Small Cell Lung Cancer after Surgery. *J. Cancer* 2021, 12, 2065–2072. [CrossRef]

127. Afzar, C.U.; Uysal, P. HIF-1α Levels in Patients Receiving Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Carcinoma. *Rev. Assoc. Med. Bras.* 2019, 65, 1295–1299. [CrossRef] [PubMed]

128. Ostheimer, C.; Bache, M.; Güttler, A.; Kotzsch, M.; Vordermark, D. A Pilot Study on Potential Plasma Hypoxia Markers in the Radiotherapy of Non-Small Cell Lung Cancer. Osteopontin, Carbonic Anhydrase IX and Vascular Endothelial Growth Factor. *Strahlenther. Onkol.* 2014, 190, 276–282. [CrossRef]
162. Schwartz, J.; Grkovic, M.; Rimner, A.; Schüder, H.; Zanzonico, P.B.; Carlin, S.D.; Staton, K.D.; Humm, J.L.; Nehmeh, S.A. Pharmacokinetic Analysis of Dynamic 18F-Fluoromisonidazole PET Data in Non-Small Cell Lung Cancer. J. Nucl. Med. 2017, 58, 911–919. [CrossRef]

163. Thureau, S.; Chaumet-Riffaud, P.; Modzelewski, R.; Fernandez, P.; Tessonnier, L.; Vervueren, L.; Cachin, F.; Berriolo-Riedinger, A.; Olivier, P.; Kolesnikov-Gauthier, H.; et al. Interobserver Agreement of Qualitative Analysis and Tumor Delineation of 18F-Fluoromisonidazole and 3'-Deoxy-3'-18F-Fluorothymidine PET Images in Lung Cancer. J. Nucl. Med. 2013, 54, 1543–1550. [CrossRef] [PubMed]

164. Texte, E.; Gouel, P.; Thureau, S.; Lequesne, J.; Barres, B.; Edet-Sanson, A.; Decazes, P.; Vera, P.; Hapdey, S. Impact of the Bayesian Penalized Likelihood Algorithm (Q.CLEAR) in Comparison with the OSEM Reconstruction on Low Contrast PET Hypoxic Images. EJNMMI Phys. 2020, 7, 28. [CrossRef]

165. Zschaeck, S.; Steinbach, J.; Troost, E.G.C. FMISO as a Biomarker for Clinical Radiation Oncology. Recent Results Cancer Res. 2016, 198, 189–201. [CrossRef] [PubMed]

166. Zegers, C.M.L.; van Elmpt, W.; Szardenings, K.; Kolb, H.; Waxman, A.; Subramaniam, R.M.; Moon, D.H.; Brunetti, J.C.; Srinivas, S.M.; Lambin, P.; et al. Repeatability of Hypoxia PET Imaging Using [18F]HX4 in Lung and Head and Neck Cancer Patients: A Prospective Multicenter Trial. Eur. J. Nucl. Med. Mol. Imaging 2015, 42, 1840–1849. [CrossRef]

167. Zegers, C.M.L.; van Elmpt, W.; Reyem, B.; Even, A.J.G.; Troost, E.G.C.; Ollers, M.C.; Hoebers, F.J.P.; Houben, R.M.A.; Eriksson, J.; Windhorst, A.D.; et al. In Vivo Quantification of Hypoxic and Metabolic Status of NSCLC Tumors Using [18F]HX4 and [18F]FDG-PET/CT Imaging. Clin. Cancer Res. 2014, 20, 6389–6397. [CrossRef] [PubMed]

168. Zegers, C.M.L.; van Elmpt, W.; Wierts, R.; Reyem, B.; Sharifi, H.; Ollers, M.C.; Hoebers, F.; Troost, E.G.C.; Wanders, R.; van Baardwijk, A.; et al. Hypoxia Imaging with [18F]HX4 PET in NSCLC Patients: Defining Optimal Imaging Parameters. Radiother. Oncol. 2013, 109, 58–64. [CrossRef]

169. Wack, I.J.; Mönnich, D.; van Elmpt, W.; Zegers, C.M.L.; Troost, E.G.C.; Zips, D.; Thorwarth, D. Comparison of [18F]-FMISO, [18F]-FAZA and [18F]HX4 for PET Imaging of Hypoxia—a Simulation Study. Acta Oncol. 2015, 54, 1370–1377. [CrossRef]

170. Peeters, S.G.J.A.; Zegers, C.M.L.; Lieuwees, N.G.; van Elmpt, W.; Eriksson, J.; van Dongen, G.A.M.S.; Dubois, L.; Lambin, P. A Comparative Study of the Hypoxia PET Tracers [18F]HX4, [18F]FAZA, and [18F]-FMISO in a Preclinical Tumor Model. Int. J. Radiat. Oncol. Biol. Phys. 2015, 91, 351–359. [CrossRef]

171. Huang, T.; Civelek, A.C.; Li, J.; Jiang, H.; Ng, C.K.; Postel, G.C.; Shen, B.; Li, X.-F. Tumor Microenvironment-Dependent 18F-FDG, 18F-Fluorothymidine, and 18F-Misonidazole Uptake: A Pilot Study in Mouse Models of Human Non-Small-Cell Lung Cancer. J. Nucl. Med. 2012, 53, 1262–1268. [CrossRef] [PubMed]

172. Yu, B.; Zhu, X.; Liang, Z.; Sun, Y.; Zhao, W.; Chen, K. Clinical Usefulness of 18F-FDG PET/CT for the Detection of Distant Metastases in Patients with Non-Small Cell Lung Cancer at Initial Staging: A Meta-Analysis. Cancer Manag. Res. 2018, 10, 1859–1864. [CrossRef]

173. Heiden, B.T.; Chen, G.; Hermann, M.; Brown, R.K.J.; Orringer, M.B.; Lin, J.; Chang, A.C.; Carroll, P.W.; Lynch, W.R.; Zhao, L.; et al. 18F-FDG PET Intensity Correlates with a Hypoxic Gene Signature and Other Oncogenic Abnormalities in Operable Non-Small Cell Lung Cancer. PLoS ONE 2018, 13, e0199970. [CrossRef]

174. Thureau, S.; Modzelewski, R.; Bohn, P.; Hapdey, S.; Gouel, P.; Dubray, B.; Vera, P. Comparison of Hypermetabolic and Hypoxic Volumes Delineated on [18F]FDG and [18F]Fluoromisonidazole PET/CT in Non-Small-Cell Lung Cancer Patients. Mol. Imaging Biol. 2019. [CrossRef] [PubMed]

175. Sanduleanu, S.; van der Wiel, A.M.A.; Lieverse, R.J.V.; Marcus, D.; Ibrahim, A.; Primakov, S.; Wu, G.; Theys, J.; Yakonova, A.; Dubois, L.J.; et al. Hypoxia PET Imaging with [18F]-HX4-A Promising Next-Generation Tracer. Cancers 2020, 12, 1322. [CrossRef]

176. Vera, P.; Bohn, P.; Edet-Sanson, A.; Salles, A.; Hapdey, S.; Gardin, I.; Menard, J.-F.; Modzelewski, R.; Thiberville, L.; Dubray, B. Simultaneous Positron Emission Tomography (PET) Assessment of Metabolism with 18F-Fluoro-2-Deoxy-d-Glucose (FDG), Proliferation with 18F-Fluoro-Fluorothyridine (FLT), and Hypoxia with 18F-fluoro-Misonidazole (FMISO) before and during Radiotherapy in Patients with Non-Small-Cell Lung Cancer (NSCLC): A Pilot Study. Radiother. Oncol. 2011, 98, 109–116. [CrossRef]

177. Manafi-Farid, R.; Karamzade-Ziarati, N.; Vali, R.; Mottaghy, F.M.; Beheshti, M. 2-[18F]FDG PET/CT Radiomics in Lung Cancer: An Overview of the Technical Aspect and Its Emerging Role in Management of the Disease. Methods 2020. [CrossRef]

178. van Elmpt, W.; Zegers, C.M.L.; Reyem, B.; Even, A.J.G.; Dingemans, A.-M.C.; Ollers, M.; Wildberger, J.E.; Mottaghy, F.M.; Das, M.; Troost, E.G.C.; et al. Multiparametric Imaging of Patient and Tumour Heterogeneity in Non-Small-Cell Lung Cancer: Quantification of Tumour Hypoxia, Metabolism and Perfusion. Eur. J. Nucl. Med. Mol. Imaging 2016, 43, 240–248. [CrossRef] [PubMed]

179. Ostheimer, C.; Schweyer, F.; Reese, T.; Bache, M.; Vordermark, D. The Relationship between Tumor Volume Changes and Serial Plasma Osteopontin Detection during Radiotherapy of Non-Small-Cell Lung Cancer. Oncol. Lett. 2016, 12, 3449–3456. [CrossRef]

180. Rolfo, C.; Mack, P.C.; Scagliotti, G.V.; Baas, P.; Barlesi, F.; Bivona, T.G.; Herbst, R.S.; Mok, T.S.; Peled, N.; Pirker, R.; et al. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. J. Thorac. Oncol. 2018, 13, 1248–1268. [CrossRef] [PubMed]

181. Cortese, R.; Almendros, I.; Wang, Y.; Gozal, D. Tumor Circulating DNA Profiling in Xenografted Mice Exposed to Intermittent Hypoxia. Oncotarget 2015, 6, 556–569. [CrossRef] [PubMed]
206. Pernemalm, M.; De Petris, L.; Branca, R.M.; Forshed, J.; Kanter, L.; Soria, J.-C.; Girard, P.; Validire, P.; Pawitan, Y.; van den Oord, J.; et al. Quantitative Proteomics Profiling of Primary Lung Adenocarcinoma Tumors Reveals Functional Perturbations in Tumor Metabolism. *J. Proteome Res.* 2015, 13, 3934–3943. [CrossRef]

207. Ping, W.; Jiang, W.-Y.; Chen, W.-S.; Sun, W.; Fu, X.-N. Expression and Significance of Hypoxia Inducible Factor-1α and Lysyl Oxidase in Non-Small Cell Lung Cancer. *Asian Pac. J. Cancer Prev.* 2013, 14, 3613–3618. [CrossRef] [PubMed]

208. Carrillo de Santa Pau, E.; Arias, F.C.; Caso Pelaize, E.; Muñoz Molina, G.M.; Sánchez Hernández, I.; Muguruza Trueba, I.; Moreno Balsalobre, R.; Sacristán López, S.; Gómez Pinillos, A.; del Val Toledo Lobo, M. Prognostic Significance of the Expression of Vascular Endothelial Growth Factors A, B, C, and D and Their Receptors R1, R2, and R3 in Patients with Nonsmall Cell Lung Cancer. *Cancer* 2009, 115, 1701–1712. [CrossRef] [PubMed]

209. Feng, Y.; Wang, W.; Hu, J.; Ma, J.; Zhang, Y.; Zhang, J. Expression of VEGF-C and VEGF-D as Significant Markers for Assessment of Lymphangiogenesis and Lymph Node Metastasis in Non-Small Cell Lung Cancer. *Anat. Rec.* 2010, 293, 802–812. [CrossRef] [PubMed]

210. Saintigny, P.; Kambouchner, M.; Ly, M.; Gomes, N.; Sainte-Catherine, O.; Vassy, R.; Czernichow, S.; Letoumelin, P.; Brea, J.-L.; Berndaud, J.-F.; et al. Vascular Endothelial Growth Factor-C and Its Receptor VEGFR-3 in Non-Small-Cell Lung Cancer: Concurrent Expression in Cancer Cells from Primary Tumour and Metastatic Lymph Node. *Lung Cancer* 2007, 58, 205–213. [CrossRef] [PubMed]

211. Maekawa, S.; Iwasaki, A.; Shirakusa, T.; Enatsu, S.; Kawakami, T.; Kuroki, M.; Kuroki, M. Correlation between Lymph Node Metastasis and the Expression of VEGF-C, VEGF-D and VEGFR-3 in T1 Lung Adenocarcinoma. *Anticancer Res.* 2007, 27, 3735–3741. [PubMed]

212. Takizawa, H.; Kondo, K.; Fujino, H.; Kenzaki, K.; Miyoshi, T.; Sakiyama, S.; Tangoku, A. The Balance of VEGF-C and VEGFR-3 mRNA Is a Predictor of Lymph Node Metastasis in Non-Small Cell Lung Cancer. *Br. J. Cancer* 2006, 95, 75–79. [CrossRef] [PubMed]

213. Lee, S.J.; Lee, S.Y.; Jeon, H.-S.; Park, S.H.; Jang, J.S.; Lee, G.Y.; Son, J.W.; Kim, C.H.; Lee, W.K.; Kam, S.; et al. Vascular Endothelial Growth Factor Gene Polymorphisms and Risk of Primary Lung Cancer. *Cancer Epidemiol. Biomark. Prev.* 2005, 14, 571–575. [CrossRef] [PubMed]

214. Liu, C.; Zhou, X.; Gao, F.; Qi, Z.; Zhang, Z.; Guo, Y. Correlation of Genetic Polymorphism of Vascular Endothelial Growth Factor Gene with Susceptibility to Lung Cancer. *Cancer Gene Ther.* 2015, 22, 312–316. [CrossRef] [PubMed]

215. Zhai, R.; Liu, G.; Zhou, W.; Su, L.; Heist, R.S.; Lynch, T.J.; Wain, J.C.; Asomaning, K.; Lin, X.; Christiani, D.C. Vascular Endothelial Growth Factor Genotypes, Haplotypes, Gender, and the Risk of Non-Small Cell Lung Cancer. *Clin. Cancer Res.* 2008, 14, 612–617. [CrossRef] [PubMed]

216. Yang, F.; Qin, Z.; Shao, C.; Liu, W.; Ma, L.; Shu, Y.; Shen, H. Association between VEGF Gene Polymorphisms and the Susceptibility to Lung Cancer: An Updated Meta-Analysis. *Biomed. Res. Int.* 2018, 2018, 9271215. [CrossRef]

217. Zhao, H.-L.; Yu, J.-H.; Huang, L.-S.; Li, P.-Z.; Lao, M.; Zhu, B.; Ou, C. Relationship between Vascular Endothelial Growth Factor -2578C > a Gene Polymorphism and Lung Cancer Risk: A Meta-Analysis. *BMC Med. Genet.* 2020, 21, 17. [CrossRef]

218. Li, H.-N.; He, T.; Zha, Y.-J.; Du, F.; Liu, J.; Lin, H.-R.; Yang, W.-Z. HIF-1α Rs11549465 C>T Polymorphism Contributes to Increased Cancer Susceptibility: Evidence from 49 Studies. *J. Cancer* 2019, 10, 5955–5963. [CrossRef] [PubMed]

219. Yan, Q.; Chen, P.; Wang, S.; Liu, N.; Zhao, P.; Gu, A. Association between HIF-1α C1772T/G1790A Polymorphisms and Cancer Susceptibility: An Updated Systematic Review and Meta-Analysis Based on 40 Case-Control Studies. *BMC Cancer* 2014, 14, 950. [CrossRef]

220. Xu, S.; Ying, K. Association between HIF-1α Gene Polymorphisms and Lung Cancer: A Meta-Analysis. *Medicine* 2020, 99, e20610. [CrossRef] [PubMed]

221. Burdett, S.; Pignon, J.P.; Tierney, J.; Tribodet, H.; Stewart, L.; Le Peuchoux, C.; Aupérin, A.; Le Chevalier, T.; Stephens, R.J.; Arriagada, R.; et al. Adjuvant Chemotherapy for Resected Early-Stage Non-Small-Stage Lung Cancer. *Cochrane Database Syst. Rev.* 2015, CD011430. [CrossRef]

222. Hui, E.P.; Chan, A.T.C.; Pezzella, F.; Turley, H.; To, K.-F.; Poon, T.C.W.; Zee, B.; Mo, F.; Teo, P.M.L.; Huang, D.P.; et al. Coexpression of Hypoxia-Inducible Factors 1α and 2α, Carbonic Anhydrase IX, and Vascular Endothelial Growth Factor in Nasopharyngeal Carcinoma and Relationship to Survival. *Clin. Cancer Res.* 2002, 8, 2595–2604. [CrossRef]

223. Yohena, T.; Yoshino, I.; Takenaka, T.; Kameyama, T.; Ohba, T.; Kuniyoshi, Y.; Maehara, Y. Upregulation of Hypoxia-Inducible Factor-1α MRNA and Its Clinical Significance in Non-Small Cell Lung Cancer. *J. Thorac. Oncol.* 2009, 4, 284–290. [CrossRef] [PubMed]

224. Honguero Martínez, A.F.; Arnaud Obret, A.; Figuerola Almazán, S.; Martínez Hernández, N.; Guijarro Jorge, R. Prognostic value of the expression of vascular endothelial growth factor A and hypoxia-inducible factor 1α in patients undergoing surgery for non-small cell lung cancer. *Med. Clin.* 2014, 142, 432–437. [CrossRef] [PubMed]

225. Kim, S.J.; Rabbani, Z.N.; Dewhirst, M.W.; Vujaskovic, Z.; Vollmer, R.T.; Schreiber, E.-G.; Oosterwijk, E.; Kelley, M.J. Expression of HIF-1α, CA IX, VEGF, and MMP-9 in Surgically Resected Non-Small Cell Lung Cancer. *Lung Cancer* 2005, 49, 325–335. [CrossRef] [PubMed]

226. Zheng, C.-L.; Qiu, C.; Shen, M.-X.; Qu, X.; Zhang, T.-H.; Zhang, J.-H.; Du, J.-J. Prognostic Impact of Expression of Vascular Endothelial Growth Factor Family Expression in Patients with Non-Small Cell Lung Cancer: An Updated Meta-Analysis. *Asian Pac. J. Cancer Prev.* 2015, 16, 1881–1895. [CrossRef]
251. Pacheco, J.M.; Camidge, D.R.; Doebele, R.C.; Schenk, E. A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-Small Cell Lung Cancer. *Front. Oncol.* 2019, 9, 195. [CrossRef] [PubMed]

252. Paz-Ares, L.; Luft, A.; Vicente, D.; Tafreshi, A.; Gümüş, M.; Mazières, J.; Hermes, B.; Şenler, F.C.; Csösz, T.; Fülöp, A.; et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. *N. Engl. J. Med.* 2018, 379, 2040–2051. [CrossRef] [PubMed]

253. Gandhi, L.; Rodríguez-Abreu, D.; Gadgeel, S.; Esteban, E.; Felip, E.; De Angelis, F.; Domine, M.; Clingan, P.; Hochmair, M.J.; Powell, S.F.; et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. *N. Engl. J. Med.* 2018, 378, 2078–2092. [CrossRef] [PubMed]

254. Manoochehr Khoshinani, H.; Afshar, S.; Najafi, R. Hypoxia: A Double-Edged Sword in Cancer Therapy. *Cancer Investig.* 2016, 34, 536–545. [CrossRef]

255. Li, R.; Gu, J.; Heymach, J.V.; Shu, X.; Zhao, L.; Han, B.; Ye, Y.; Roth, J.; Wu, X. Hypoxia Pathway Genetic Variants Predict Survival of Non-Small-Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy. *Carcinogenesis* 2017, 38, 419–424. [CrossRef]

256. Wu, F.; Zhang, J.; Liu, Y.; Zheng, Y.; Hu, N. HIF1α Genetic Variants and Protein Expressions Determine the Response to Platinum Based Chemotherapy and Clinical Outcome in Patients with Advanced NSCLC. *Cell. Physiol. Biochem.* 2013, 32, 1566–1576. [CrossRef]

257. Shingyoji, M.; Ando, S.; Nishimura, H.; Nakajima, T.; Ishikawa, A.; Itakura, M.; Iizasa, T.; Kimura, H. VEGF in Patients with Non-Small Cell Lung Cancer during Combination Chemotherapy of Carboplatin and Paclitaxel. *Anticancer Res.* 2009, 29, 2635–2639. [PubMed]

258. Naumnik, W.; Izycki, T.; Swidzińska, E.; Ossolińska, M.; Chyczewska, E. Serum Levels of VEGF-C, VEGF-D, and SVEGF-R2 in Patients with Lung Cancer during Chemotherapy. *Oncol. Res.* 2007, 16, 445–451. [CrossRef] [PubMed]

259. Zeng, L.; Kizaka-Kondoh, S.; Itasaka, S.; Xie, X.; Inoue, M.; Tanimoto, K.; Shibuya, K.; Hiraoka, M. Hypoxia Inducible Factor-1 Influences Sensitivity to Paclitaxel of Human Lung Cancer Cell Lines under Normoxic Conditions. *Cancer Sci.* 2007, 98, 1394–1401. [CrossRef] [PubMed]

260. Sowa, T.; Menju, T.; Chen-Yoshikawa, T.F.; Takahashi, K.; Nishikawa, S.; Nakanishi, T.; Shikuma, K.; Motoyama, H.; Hijiya, K.; Aoyama, A.; et al. Hypoxia-Inducible Factor 1 Promotes Chemoresistance of Lung Cancer by Inducing Carbonic Anhydrase IX Expression. *Cancer Med.* 2017, 6, 288–297. [CrossRef]

261. Guo, Q.; Lan, F.; Yan, X.; Xiao, Z.; Wu, Y.; Zhang, Q. Hypoxia Exposure Induced Cisplatin Resistance Partially via Activating P53 and Hypoxia Inducible Factor-1α in Non-Small Cell Lung Cancer A549 Cells. *Oncol. Lett.* 2018, 16, 801–808. [CrossRef] [PubMed]

262. Deben, C.; Deschoolmeester, V.; De Waele, J.; Jacobs, J.; Van den Bossche, J.; Wouters, A.; Peeters, M.; Rolfo, C.; Smits, E.; Lardon, F.; et al. Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant P53 and Can Be Overcome by Induction of Oxidative Stress. *Cancers* 2018, 10, 126. [CrossRef]

263. Zhang, F.; Duan, S.; Tsai, Y.; Keng, P.C.; Chen, Y.; Lee, S.O.; Chen, Y. Cisplatin Treatment Increases Stemness through Upregulation of Hypoxia-Inducible Factors by Interleukin-6 in Non-Small Cell Lung Cancer. *Cancer Sci.* 2016, 107, 746–754. [CrossRef] [PubMed]

264. Shi, Y.; Fan, S.; Wu, M.; Zuo, Z.; Li, X.; Jiang, L.; Shen, Q.; Xu, P.; Zeng, L.; Zhou, Y.; et al. YTHDF1 Links Hypoxia Adaptation and Non-Small Cell Lung Cancer Progression. *Nat. Commun.* 2019, 10, 4892. [CrossRef] [PubMed]

265. Lu, Y.; Yu, L.-Q.; Zhu, L.; Zhao, N.; Zhou, X.-J.; Lu, X. Expression of HIF-1α and P-Gp in Non-Small Cell Lung Cancer and the Relationship with HPV Infection. *Oncol. Lett.* 2012, 6, 1455–1459. [CrossRef] [PubMed]

266. Shen, X.; Zhi, Q.; Wang, Y.; Li, Z.; Zhou, J.; Huang, J. Hypoxia Induces Multidrug Resistance via Enhancement of Epidermal Growth Factor-Like Domain 7 Expression in Non-Small Lung Cancer Cells. *Chemotherapy* 2017, 62, 172–180. [CrossRef] [PubMed]

267. Liu, S.; Qin, T.; Jia, Y.; Li, K. PD-L1 Expression Is Associated with VEGFA and LADC Patients’ Survival. *Front. Oncol.* 2019, 9, 189. [CrossRef]

268. Cubillos-Zapata, C.; Almendros, I.; Díaz-García, E.; Toledano, V.; Casitas, R.; Galera, R.; López-Collazo, E.; Farre, R.; Gozal, D.; García-Rio, F. Differential Effect of Intermittent Hypoxia and Sleep Fragmentation on PD-1/PD-L1 Uptregulation. *Sleep* 2020, 43. [CrossRef]

269. Huang, M.-H.; Zhang, X.-B.; Wang, H.-L.; Li, L.-X.; Zeng, Y.-M.; Wang, M.; Zeng, H.-Q. Intermittent Hypoxia Enhances the Tumor Programmed Death Ligand 1 Expression in a Mouse Model of Sleep Apnea. *Ann. Transl. Med.* 2019, 7, 97. [CrossRef] [PubMed]

270. Cubillos-Zapata, C.; Balbás-García, C.; Avendaño-Ortiz, J.; Toledano, V.; Torres, M.; Almendros, I.; Casitas, R.; Zamarrón, E.; García-Sánchez, A.; Felu, J.; et al. Age-Dependent Hypoxia-Induced PD-L1 Uptregulation in Patients with Obstructive Sleep Apnoea. *Respirology* 2019, 24, 684–692. [CrossRef] [PubMed]

271. Chang, W.H.; Lai, A.G. aberrations in notch-hedgehog signalling reveal cancer stem cells harbouring conserved oncogenic properties associated with hypoxia and immune evasion. *Br. J. Cancer* 2019, 121, 666–678. [CrossRef]

272. Hattfield, S.; Veseleleva, K.; Steingold, J.; Sethuraman, J.; Sitkovsky, M. Mechanistic Justifications of Systemic Therapeutic Oxygenation of Tumors to Weaken the Hypoxia Inducible Factor 1α-Mediated Immunosuppression. *Adv. Exp. Med. Biol.* 2019, 1136, 113–121. [CrossRef] [PubMed]

273. Hattfield, S.M.; Kjaergaard, J.; Lukashev, D.; Schreiber, T.H.; Belikoff, B.; Abbott, R.; Sethumadhavan, S.; Philbrook, P.; Ko, K.; Cannici, R.; et al. Immunological Mechanisms of the Antitumor Effects of Supplemental Oxygenation. *Sci. Transl. Med.* 2015, 7, 277ra30. [CrossRef] [PubMed]
Cancers 2021, 13, 3421

274. Eckert, F.; Zwirner, K.; Boeke, S.; Thorwarth, D.; Zips, D.; Huber, S.M. Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients with Hypoxic Tumors. Front. Immunol. 2019, 10, 407. [CrossRef] [PubMed]

275. Dewhirst, M.W.; Mowery, Y.M.; Mitchell, J.B.; Cherukuri, M.K.; Secomb, T.W. Rationale for Hypoxia Assessment and Amelioration for Precision Therapy and Immunotherapy Studies. J. Clin. Investig. 2019, 129, 489–491. [CrossRef]

276. Carbone, F.; Grossi, F.; Bonaventura, A.; Vecchione, A.; Minetti, S.; Barbi, N.; Elia, E.; Ansaldi, A.M.; Ferrara, D.; Rijavec, E.; et al. Baseline Serum Levels of Osteopontin Predict Clinical Response to Treatment with Nivolumab in Patients with Non-Small Cell Lung Cancer. Clin. Exp. Metastasis 2019, 36, 449–456. [CrossRef] [PubMed]

277. Stieb, S.; Eleftheriou, A.; Warnock, G.; Guenkenberger, M.; Risticker, O. Longitudinal PET Imaging of Tumor Hypoxia during the Course of Radiotherapy. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 2201–2217. [CrossRef]

278. Eschmann, S.M.; Paulsen, F.; Reimold, M.; Dittmann, H.; Welz, S.; Reischl, G.; Machulla, H.J.; Bares, R. Prognostic Impact of Hypoxia Imaging with 18F-Misonidazole PET in Non-Small Cell Lung Cancer and Head and Neck Cancer before Radiotherapy. J. Nucl. Med. 2005, 46, 253–260. [PubMed]

279. Yang, Y.; Han, G; Xu, W. The Diagnostic Value of 99mTc-2-(2-Methyl-5-Nitro-1H-Imidazol-1-Yl) Ethyl Dihydrogen Phosphate Hypoxia Imaging and Its Evaluation Performance for Radiotherapy Efficacy in Non-Small-Cell Lung Cancer. Onco Targets Ther. 2016, 9, 6499–6509. [CrossRef] [PubMed]

280. Watanabe, S.; Inoue, T.; Okamoto, S.; Magota, K.; Takayanagi, A.; Sakakibara-Konishi, J.; Katoh, N.; Hirata, K.; Manabe, O.; Toyonaga, T.; et al. Combination of FDG-PET and FMISO-PET as a Treatment Strategy for Patients Undergoing Early-Stage NSCLC Stereotactic Radiotherapy. EJNMMI Res. 2019, 9, 104. [CrossRef]

281. Li, L.; Yu, J.; Xing, L.; Ma, K.; Zhu, H.; Guo, H.; Sun, X.; Li, J.; Yang, G.; Li, W.; et al. Serial Hypoxia Imaging with 99mTc-HL91 SPECT to Predict Radiotherapy Response in Nonsmall Cell Lung Cancer. Am. J. Clin. Oncol. 2006, 29, 628–633. [CrossRef] [PubMed]

282. Grootjans, W.; de Geus-Oei, L.F.; Bussink, J. Image-Guided Adaptive Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer: The Art of PET. J. Nucl. Med. Mol. Imaging 2018, 62, 369–384. [CrossRef] [PubMed]

283. Bollineni, V.R.; Wiegman, E.M.; Pruim, J.; Groen, H.J.M.; Langendijk, J.A. Hypoxia Imaging Using Positron Emission Tomography in Non-Small Cell Lung Cancer: Implications for Radiotherapy. Cancer Treat. Rev. 2012, 38, 1027–1032. [CrossRef] [PubMed]

284. Askoxylakis, V.; Dinkel, J.; Eichinger, M.; Stieltjes, B.; Sommer, G.; Strauss, L.G.; Dimitrakopoulou-Strauss, A.; Kopp-Schneider, A.; Haberkorn, U.; Huber, P.E.; et al. Multimodal Hypoxia Imaging and Intensity Modulated Radiation Therapy for Unresectable Non-Small-Cell Lung Cancer: The HIL Trial. Radiat. Oncol. 2012, 7, 157. [CrossRef]

285. Li, H.; Xu, D.; Han, X.; Ruan, Q.; Zhang, X.; Mi, Y.; Dong, M.; Guo, S.; Lin, Y.; Wang, B.; et al. Dosimetry Study of 18F-FMISO + PET/CT Hypoxia Imaging Guidance on Intensity-Modulated Radiation Therapy for Non-Small Cell Lung Cancer. Clin. Transl. Oncol. 2018, 20, 1329–1336. [CrossRef] [PubMed]

286. Horsman, M.R.; Mortensen, L.S.; Petersen, J.B.; Busk, M.; Overgaard, J. Imaging Hypoxia to Improve Radiotherapy Outcome. Nat. Rev. Clin. Oncol. 2012, 9, 674–687. [CrossRef] [PubMed]

287. Vera, P.; Mihailescu, S.-D.; Lequesne, J.; Modzelewski, R.; Bohn, P.; Hapdey, S.; Pépin, L.-F.; Dubray, B.; Chaumet-Riffaud, P.; Decazes, P.; et al. Radiotherapy Boost in Patients with Hypoxic Lesions Identified by 18F-FMISO PET/CT in Non-Small-Cell Lung Carcinoma: Can We Expect a Better Survival Outcome without Toxicity? [RTEP5 Long-Term Follow-Up]. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 1448–1456. [CrossRef]

288. Yang, L.; West, C.M. Hypoxia Gene Expression Signatures as Predictive Biomarkers for Personalisation Radiotherapy. Br. J. Radiol. 2019, 92, 20180036. [CrossRef] [PubMed]

289. Peitzsch, C.; Perrin, R.; Hill, R.P.; Dubrovskva, A.; Kurth, I. Hypoxia as a Biomarker for Radioresistant Cancer Stem Cells. Int. J. Radiat. Biol. 2014, 90, 636–652. [CrossRef]

290. Sörensen, B.S.; Horsman, M.R. Tumor Hypoxia: Impact on Radiotherapy and Molecular Pathways. Front. Oncol. 2020, 10, 562. [CrossRef]

291. Moreno Roig, E.; Groot, A.J.; Yaromina, A.; Hendrickx, T.C.; Barbeau, L.M.O.; Giuranno, L.; Dams, G.; Ient, J.; Olof Pimentel, V.; van Gisbergen, M.W.; et al. Expression of HIF-1α and HIF-2α Differently Regulate the Radiation Sensitivity of NSCLC Cells. Cells 2019, 8, 45. [CrossRef] [PubMed]

292. Harada, H. Hypoxia-Inducible Factor 1-Mediated Characteristic Features of Cancer Cells for Tumor Radioresistance. J. Radiat. Res. 2016, 57 (Suppl. 1), i99–i105. [CrossRef]

293. Gong, C.; Gu, R.; Jin, H.; Sun, Y.; Li, Z.; Chen, J.; Wu, G. Lysyl Oxidase Mediates Hypoxia-Induced Radioresistance in Non-Small Cell Lung Cancer A549 Cells. Exp. Biol. Med. 2016, 241, 387–395. [CrossRef]

294. Gu, Q.; He, Y.; Ji, J.; Yao, Y.; Shen, W.; Luo, J.; Zhu, W.; Cao, H.; Geng, Y.; Xu, J.; et al. Hypoxia-Inducible Factor 1α (HIF-1α) and Reactive Oxygen Species (ROS) Mediates Radiation-Induced Invasiveness through the SDF-1α/CXCR4 Pathway in Non-Small Cell Lung Carcinoma Cells. Oncotarget 2015, 6, 10893–10907. [CrossRef] [PubMed]

295. Schilling, D.; Bayer, C.; Li, W.; Molls, M.; Vaupel, P.; Multhoff, G. Radiosensitization of Normoxic and Hypoxic H1339 Lung Tumor Cells by Heat Shock Protein 90 Inhibition Is Independent of Hypoxia Inducible Factor-1alpha. Cancer Res. 2009, 69, 1624–1632. [CrossRef] [PubMed]
Cancers 2021, 13, 3421

297. Devlin, C.; Greco, S.; Martelli, F.; Ivan, M. MiR-210: More than a Silent Player in Hypoxia. JUMMB Life 2011, 63, 94–100. [CrossRef]

298. Grosso, S.; Doyen, J.; Parks, S.K.; Bertero, T.; Paye, A.; Cardinaud, B.; Gounon, P.; Lacas-Gervais, S.; Noël, A.; Pouysségur, J.; et al. MiR-210 Promotes a Hypoxic Phenotype and Increases Radiosensitivity in Human Lung Cancer Cell Lines. Cell Death Dis. 2013, 4, e545. [CrossRef] [PubMed]

299. Saki, M.; Makino, H.; Javvadi, P.; Tomimatsu, N.; Ding, L.-H.; Clark, J.E.; Gavin, E.; Takeda, K.; Andrews, J.; Saha, D.; et al. EGFR Mutations Compromise Hypoxia-Associated Radiation Resistance through Impaired Replication Fork-Associated DNA Damage Repair. Mol. Cancer Res. 2017, 15, 1503–1516. [CrossRef]

300. Yang, H.; Liang, S.-Q.; Schmid, R.A.; Peng, R.-W. New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness. Front. Oncol. 2019, 9, 953. [CrossRef]

301. Aran, V.; Omerovic, J. Current Approaches in NSCLC Targeting K-RAS and EGFR. Int. J. Mol. Sci. 2019, 20, 5701. [CrossRef]

302. De la Garza, M.M.; Cumpian, A.M.; Daliri, S.; Castro-Pando, S.; Umer, M.; Gong, L.; Khosravi, N.; Caetano, M.S.; Ramos-Castañeda, M.; Flores, A.G.; et al. COPD-Type Lung Inflammation Promotes K-Ras Mutant Lung Cancer through Epithelial HIF-1α Mediated Tumor Angiogenesis and Proliferation. Oncotarget 2018, 9, 32972–32983. [CrossRef] [PubMed]

303. Park, S.; Ha, S.Y.; Cho, H.Y.; Chung, D.H.; Kim, N.R.; Hong, J.; Cho, E.K. Prognostic Implications of Hypoxia-Inducible Factor-1α Expression in Lung Cancer Patients (SAKK 19/05 Trial). Clin. Cancer Res. 2015, 21, 5253–5263. [CrossRef] [PubMed]

304. Pore, N.; Jiang, Z.; Gupta, A.; Cerniglia, G.; Kao, G.D.; Maity, A. EGFR Tyrosine Kinase Inhibitors Decrease VEGF Expression Counteracted by Prima-1 and Reversed by N-Acetylcysteine. BMC Cancer 2016, 16, 902. [CrossRef] [PubMed]

305. Yoshikawa, Y.; Takahashi, F.; Nara, T.; Hashimoto, M.; Tajima, K.; Murakami, A.; Nurwidya, F.; Yae, S.; Koizumi, F.; Minakata, K.; Takahashi, F.; et al. Ras Inhibitors Display an Anti-Metastatic Effect by Induction of an Immunosuppressive pro-Tumor Microenvironment. Oncoimmunology 2016, 5, e129724. [CrossRef] [PubMed]

306. Orue, A.; Chavez, V.; Strasberg-Rieber, M.; Rieber, M. Hypoxic Resistance of KRAS Mutant Tumor Cells to 3-Bromopyruvate Is Mediated Tumor Angiogenesis and Proliferation. Oncotarget 2018, 17, 38. [CrossRef]

307. Shepherd, F.A.; Rodrigues Pereira, J.; Ciuleanu, T.; Tan, E.H.; Hirsh, V.; Thongprasert, S.; Campos, D.; Maoleekoopiroj, S.; Smylie, M.; Martins, R.; et al. Erlotinib in Previously Treated Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2005, 353, 123–132. [CrossRef]

308. An, S.-M.; Lei, H.-M.; Ding, X.-P.; Sun, F.; Zhang, C.; Tang, Y.-B.; Chen, H.-Z.; Shen, Y.; Zhu, L. Interleukin-6 Identified as an Important Factor in Hypoxia-Induced Factor-1α-Mediated Tumor Angiogenesis and Proliferation. Cancer Lett. 2017, 410, 82–91. [CrossRef] [PubMed]

309. Park, S.; Ha, S.Y.; Cho, H.Y.; Chung, D.H.; Kim, N.R.; Hong, J.; Cho, E.K. Prognostic Implications of Hypoxia-Inducible Factor-1α Expression in Lung Cancer Patients (SAKK 19/05 Trial). Clin. Cancer Res. 2015, 21, 5253–5263. [CrossRef] [PubMed]

310. Aran, V.; Omerovic, J. Current Approaches in NSCLC Targeting K-RAS and EGFR. Int. J. Mol. Sci. 2019, 20, 5701. [CrossRef]

311. Murakami, A.; Takahashi, F.; Nurwidya, F.; Kobayashi, I.; Minakata, K.; Hashimoto, M.; Nara, T.; Kato, M.; Tajima, K.; Shimada, N.; et al. Hypoxia Increases Gefitinib-Resistant Lung Cancer Stem Cells through Activation of Insulin-like Growth Factor Receptor (EGFR) to EGFR-Targeted Therapy Are Linked to Downregulation of Hypoxia-Inducible Factor-1α. J. Cancer Res. 2017, 29, 1645–1657. [CrossRef]

312. Franzini, A.; Baty, F.; Macovei, I.I.; Dürr, O.; Droege, C.; Betticher, D.; Grigoriu, B.D.; Klingbiel, D.; Zappa, F.; Brutsche, M.H. Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non-Small Cell Lung Cancer. Clin. Lung Cancer 2012, 13, 2616–2627. [CrossRef] [PubMed]

313. Minakata, K.; Takahashi, F.; Nara, T.; Hashimoto, M.; Tajima, K.; Murakami, A.; Nurwidya, F.; Yae, S.; Koizumi, F.; Moriyama, H.; et al. Hypoxia Induces Gefitinib Resistance in Non-Small-Cell Lung Cancer with Both Mutant and Wild-Type Epidermal Growth Factor Receptor Mutations. Cancer Sci. 2013, 104, 1503–1516. [CrossRef] [PubMed]

314. Lu, Y.; Liang, K.; Li, X.; Fan, Z. Responses of Cancer Cells with Wild-Type or Tyrosine Kinase Domain-Mutated Epidermal Growth Factor Receptor (EGFR) to EGFR-Targeted Therapy Are Linked to Downregulation of Hypoxia-Inducible Factor-1α. Mol. Cancer Lett. 2011, 5, 1556. [CrossRef]

315. Lu, Y.; Liang, K.; Li, X.; Fan, Z.; Zhang, C.; Tang, Y.-B.; Chen, H.-Z.; Shen, Y.; Zhu, L. Interleukin-6 Identified as an Important Factor in Hypoxia-Inducible Factor-1α-Mediated Tumor Angiogenesis and Proliferation. Cancer Lett. 2017, 410, 82–91. [CrossRef] [PubMed]

316. Yoshikawa, Y.; Takano, O.; Kato, I.; Takahashi, Y.; Shima, F.; Kataoka, Y.; Murakami, A.; Nurwidya, F.; Yae, S.; Koizumi, F.; Minakata, K.; Takahashi, F.; et al. Ras Inhibitors Display an Anti-Metastatic Effect by Downregulation of Lysyl Oxidase through Inhibition of the Ras-P13K-Akt-HIF-1α Pathway. Cancer Lett. 2017, 410, 82–91. [CrossRef] [PubMed]

317. Orue, A.; Chavez, V.; Strasberg-Rieber, M.; Rieber, M. Hypoxic Resistance of KRAS Mutant Tumor Cells to 3-Bromopyruvate Is Counteracted by Prima-1 and Reversed by N-Acetylcysteine. BMC Cancer 2016, 16, 902. [CrossRef] [PubMed]

318. An, S.-M.; Lei, H.-M.; Ding, X.-P.; Sun, F.; Zhang, C.; Tang, Y.-B.; Chen, H.-Z.; Shen, Y.; Zhu, L. Interleukin-6 Identified as an Important Factor in Hypoxia-Inducible Factor-1α-Mediated Tumor Angiogenesis and Proliferation. Cancer Lett. 2017, 410, 82–91. [CrossRef] [PubMed]

319. Kani, K.; Garri, C.; Tiemann, K.; Mallihi, P.D.; Punj, V.; Nguyen, A.L.; Lee, J.; Hughes, L.D.; Alvarez, R.M.; Wood, D.M.; et al. JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-Mutant NSCLC Cell Lines. Mol. Cancer Ther. 2017, 16, 1645–1657. [CrossRef]
Cancers 2021, 13, 3421

320. Chen, Z.; Tian, D.; Liao, X.; Zhang, Y.; Xiao, J.; Chen, W.; Liu, Q.; Chen, Y.; Li, D.; Zhu, L.; et al. Apigenin Combined With Gefitinib Blocks Autophagy Flux and Induces Apoptotic Cell Death Through Inhibition of HIF-1α, c-Myc, p-EGFR, and Glucose Metabolism in EGFR L858R-T790M-Mutated H1975 Cells. *Front. Pharmacol.* 2019, 10, 260. [CrossRef] [PubMed]

321. Kobayashi, M.; Saito, R.; Miki, Y.; Nanamiya, R.; Inoue, C.; Abe, J.; Satoh, I.; Okada, Y.; Sasano, H. The Correlation of P22phox and Chemosensitivity in EGFR-TKI Resistant Lung Adenocarcinoma. *Oncotarget* 2019, 10, 1119–1131. [CrossRef] [PubMed]

322. Lee, J.G.; Wu, R. Erlotinib-Cisplatin Combination Inhibition Increases Growth and Angiogenesis through c-MYC and HIF-1α in EGFR-Mutated Lung Cancer in Vitro and in Vivo. *Neoplasia* 2015, 17, 190–200. [CrossRef] [PubMed]

323. Saito, H.; Fukushima, T.; Furuya, N.; Watanabe, K.; Sugawara, S.; Iwasawa, S.; Tsuneyuki, Y.; Yamaguchi, O.; Okada, M.; Yoshimori, K.; et al. Erlotinib plus Bevacizumab versus Erlotinib Alone in Patients with EGFR-Positive Advanced Non-Squamous Non-Small-Cell Lung Cancer (NEJ026). *Lancet Oncol.* 2019, 20, 625–635. [CrossRef]

324. Ninomiya, T.; Ishikawa, N.; Inoue, K.; Kubo, T.; Yasugi, M.; Shibayama, T.; Maeda, T.; Fujitaka, K.; Kodani, M.; Yokoyama, T.; et al. Phase 2 Study of Afatinib Alone or Combined with Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfAfev-CS Study Protocol. *Clin. Lung Cancer* 2019, 20, 134–138. [CrossRef] [PubMed]

325. Hu, H.; Miao, X.-K.; Li, J.-Y.; Zhang, X.-W.; Xu, J.-J.; Zhang, J.-Y.; Zhou, T.-X.; Hu, M.-N.; Yang, W.-L.; Mou, L.-Y. YC-1 Potentiates the Antitumor Activity of Gefitinib by Inhibiting HIF-1α and Promoting the Endocytic Trafficking and Degradation of EGFR in Gefitinib-Resistant Non-Small-Cell Lung Cancer Cells. *Eur. J. Pharmacol.* 2020, 874, 172961. [CrossRef] [PubMed]

326. Li, F.; Mei, H.; Gao, Y.; Xie, X.; Nie, H.; Li, T.; Zhang, H.; Jia, L. Co-Delivery of Oxygen and Erlotinib by Aptamer-Modified Liposomal Complexes to Reverse Hypoxia-Induced Drug Resistance in Lung Cancer. *Biomaterials* 2017, 145, 56–71. [CrossRef]

327. Du, X.; Shao, Y.; Qin, H.-F.; Tai, Y.-H.; Gao, H.-J. ALK-Rearrangement in Non-Small-Cell Lung Cancer (NSCLC). *Thorac. Cancer* 2018, 9, 423–430. [CrossRef]

328. Martinengo, C.; Poggio, T.; Menotti, M.; Scalzo, M.S.; Mastini, C.; Ambrogio, C.; Pellegrino, E.; Riera, L.; Piva, R.; Ribatti, D.; et al. ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis. *Cancer Res.* 2014, 74, 6094–6106. [CrossRef]

329. Sharma, G.G.; Mota, I.; Molongi, L.; Patrucco, E.; Gambacorti-Passerini, C.; Chiarle, R. Tumor Resistance against ALK Targeted Therapy—Where It Comes from and Where It Goes. *Cancers* 2018, 10, 62. [CrossRef]

330. Ma, Y.; Yu, C.; Mohamed, E.M.; Shao, H.; Wang, L.; Sundaresan, J.; Zweit, J.; Ildowu, M.; Fang, X. A Causal Link from ALK to Hexokinase II Overexpression and Hyperactive Glycolysis in EML4-ALK-Positive Lung Cancer. *Oncogene* 2016, 35, 6132–6142. [CrossRef] [PubMed]

331. Kogita, A.; Togashi, Y.; Hayashi, H.; Sobage, S.; Terashima, M.; De Velasco, M.A.; Sakai, K.; Fujita, Y.; Tomida, S.; Takeyama, Y.; et al. Hypoxia Induces Resistance to ALK Inhibitors in the H3122 Non-Small Cell Lung Cancer Cell Line with an ALK Rearrangement via Epithelial-Mesenchymal Transition. *Int. J. Oncol.* 2014, 45, 1430–1436. [CrossRef] [PubMed]

332. Koh, J.; Jang, J.-Y.; Keam, B.; Kim, S.; Kim, M.-Y.; Go, H.; Kim, T.M.; Kim, D.-W.; Kim, C.-W.; Jeon, Y.K.; et al. EML4-ALK Enhances Programmed Cell Death-Ligand 1 Expression in Pulmonary Adenocarcinoma via Hypoxia-Inducible Factor (HIF)-1α and STAT3. *Oncoimmunology* 2016, 5, e1108514. [CrossRef] [PubMed]

333. Bielec, B.; Schueff, H.; Terenzii, A; Berger, W.; Heffeter, P.; Keppler, B.K.; Kowol, C.R. Development and Biological Investigations of Hypoxia-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib. *Bioorg. Chem.* 2020, 99, 103778. [CrossRef] [PubMed]

334. Denko, N.C. Hypoxia, HIF1 and Glucose Metabolism in the Solid Tumour. *Nat. Rev. Cancer* 2008, 8, 705–713. [CrossRef] [PubMed]

335. Kim, J.; Tchernyshov, I.; Semenza, G.L.; Dang, C.V. HIF-1-Mediated Expression of Pyruvate Dehydrogenase Kinase: A Metabolic Switch Required for Cellular Adaptation to Hypoxia. *Cell Metab.* 2006, 3, 177–185. [CrossRef] [PubMed]

336. Yang, R.; Guo, C. Discovery of Potent Pyruvate Dehydrogenase Kinase Inhibitors and Evaluation of Their Anti-Lung Cancer Activity under Hypoxia. *Medchemcomm* 2018, 9, 1843–1849. [CrossRef] [PubMed]

337. Liu, T.; Yin, H. PDK1 Promotes Tumor Cell Proliferation and Migration by Enhancing the Warburg Effect in Non-Small Cell Lung Cancer. *Oncol. Rep.* 2017, 37, 193–200. [CrossRef]

338. Yang, Z.; Tam, K.Y. Anti-Cancer Synergy of Dichloroacetate and EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines. *Eur. J. Pharmacol.* 2016, 789, 458–467. [CrossRef]

339. Yang, Z.; Hu, X.; Zhang, S.; Zhang, W.; Tam, K.Y. Pharmacological Synergism of 2,2-Dichloroacetophenone and EGFR-TKi to Overcome TKi-Induced Resistance in NSCLC. *Eur. J. Pharmacol.* 2017, 815, 80–87. [CrossRef] [PubMed]

340. Romero, Y.; Castillo-José-López, M.; Romero-Garcia, S.; Aguayo, A.S.; Herrera, I.; Garcia-Martin, M.O.; Torres-Espindola, L.M.; Negrete-Garcia, M.C.; Olvera, A.C.; Huerta-Cruz, J.C.; et al. Antitumor Therapy under Hypoxic Microenvironment by the Combination of 2-Methoxyestradiol and Sodium Dichloroacetate on Human Non-Small-Cell Lung Cancer. *Oxid. Med. Cell. Longev.* 2020, 2020, 3176375. [CrossRef]

341. Garon, E.B.; Christofk, H.R.; Hosmer, W.; Britten, C.D.; Bahng, A.; Crabtree, M.J.; Hong, C.S.; Kamranpour, N.; Pitts, S.; Kabbabnaïv, F.; et al. Dichloroacetate Should Be Considered with Platinum-Based Chemotherapy in Hypoxic Tumors rather than as a Single Agent in Advanced Non-Small Cell Lung Cancer. *J. Cancer Res. Clin. Oncol.* 2014, 140, 443–452. [CrossRef] [PubMed]

342. Yang, Z.; Zhang, S.-L.; Hu, X.; Tam, K.Y. Inhibition of Pyruvate Dehydrogenase Kinase 1 Enhances the Anti-Cancer Effect of EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. *Eur. J. Pharmacol.* 2018, 838, 41–52. [CrossRef] [PubMed]

343. Zahra, K.; Dey, T.; Ashish; Mishra, S.P.; Pandey, U. Pyruvate Kinase M2 and Cancer: The Role of PKM2 in Promoting Tumorigenesis. *Front. Oncol.* 2020, 10, 159. [CrossRef]
344. Guo, C.-Y.; Zhu, Q.; Tou, F.-F.; Wen, X.-M.; Kuang, Y.-K.; Hu, H. The Prognostic Value of PKM2 and Its Correlation with Tumour Cell PD-L1 in Lung Adenocarcinoma. *BMC Cancer* **2019**, *19*, 289. [CrossRef]

345. Su, Q.; Luo, S.; Tan, Q.; Deng, J.; Zhou, S.; Peng, M.; Tao, T.; Yang, X. The Role of Pyruvate Kinase M2 in Anticancer Therapeutic Treatments. *Oncol. Lett.* **2019**, *18*, 5663–5672. [CrossRef] [PubMed]

346. Mallrik, R.; Chowdhury, T.A. Metformin in Cancer. *Diabetes Res. Clin. Pract.* **2018**, *143*, 409–419. [CrossRef]

347. Chun, S.G.; Liao, Z.; Jeter, M.D.; Chang, J.Y.; Lin, S.H.; Komaki, R.U.; Guerrero, T.M.; Mayo, R.C.; Korah, B.M.; Koshiy, S.M.; et al. Metabolic Responses to Metformin in Inoperable Early-Stage Non-Small Cell Lung Cancer Treated with Stereotactic Radiotherapy: Results of a Randomized Phase II Clinical Trial. *Am. J. Clin. Oncol.* **2020**, *43*, 231–235. [CrossRef]

348. Kubo, T.; Ninomiya, T.; Hotta, K.; Kozuki, T.; Toyooka, S.; Okada, H.; Fujiwara, T.; Udon, H.; Kiura, K. Study Protocol: Phase-Ib Trial of Nivolumab Combined with Metformin for Refractory/Recurrent Solid Tumors. *Clin. Lung Cancer* **2018**, *19*, e861–e864. [CrossRef]

349. Afzal, M.Z.; Dragnev, K.; Sarwar, T.; Shirai, K. Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Receiving Concurrent Metformin and Immune Checkpoint Inhibitors. *Lung Cancer Manag.* **2019**, *8*, LMT1. [CrossRef]

350. Ahmed, I.; Ferro, A.; Kohler, A.; Langenfeld, J.; Surakanti, S.G.; Aisner, J.; Zou, W.; Haffty, B.G.; Jabour, S.K. Impact of Metformin Use on Survival Locally-Advanced, Inoperable Non-Small Cell Lung Cancer Treated with Definitive Chemoradiation. *J. Thorac. Dis.* **2015**, *7*, 346–355. [CrossRef]

351. Stang, K.; Alite, F.; Adams, W.; Altoos, B.; Melian, E.; Emami, B.; Harkenrider, M. Impact of Concurrent Coincident Use of Metformin During Lung Radiosurgery Radiation Therapy. *Cureus* **2021**, *13*, e14157. [CrossRef]

352. Wink, K.C.J.; Belderbos, J.S.A.; Dieleman, E.M.T.; Rossi, M.; Rasch, C.R.N.; Damhuis, R.A.M.; Houben, R.M.A.; Troost, E.G.C. Improved Progression Free Survival for Patients with Diabetes and Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Using Metformin during Concurrent Chemoradiotherapy. *Radiother. Oncol.* **2016**, *118*, 453–459. [CrossRef]

353. Brancher, S.; Steer, N.C.; Weiderpass, E.; Damhuis, R.A.M.; Johannesen, T.B.; Botteri, E.; Strand, T.-E. Metformin Use and Lung Cancer Survival: A Population-Based Study in Norway. *Br. J. Cancer* **2021**, *124*, 1018–1025. [CrossRef]

354. Li, L.; Jiang, L.; Wang, Y.; Zhao, Y.; Zhang, X.-J.; Wu, G.; Zhou, X.; Sun, J.; Bai, J.; Ren, B.; et al. Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial. *Clin. Cancer Res.* **2019**, *25*, 6967–6975. [CrossRef] [PubMed]

355. Zhang, B.; Xie, Z.; Li, B. The Clinicopathologic Impacts and Prognostic Significance of GLUT1 Expression in Patients with Lung Cancer: A Meta-Analysis. *Gene* **2019**, *688*, 76–83. [CrossRef]

356. Shriwas, P.; Roberts, D.; Li, Y.; Wang, L.; Qian, Y.; Bergmeier, S.; Hines, J.; Adhicary, S.; Nielsen, C.; Chen, X. A Small-Molecule Pan-Class I Glucose Transporter Inhibitor Reduces Cancer Cell Proliferation in Vitro and Tumor Growth in Vivo by Targeting Glucose-Based Metabolism. *Cancer Metab.* **2021**, *9*, 14. [CrossRef] [PubMed]

357. Hutt, D.M.; Roth, D.M.; Vignaud, H.; Cullin, C.; Boucheareil, M. The Histone Deacetylase Inhibitor, Vorinostat, Represses Hypoxia Inducible Factor 1 Alpha Expression through Translational Inhibition. *PLoS ONE* **2014**, *9*, e106224. [CrossRef]

358. Zhang, C.; Yang, C.; Feldman, M.J.; Wang, H.; Pang, Y.; Maggio, D.M.; Zhu, D.; Nesvick, C.L.; Dmitriev, P.; Bullova, P.; et al. Vorinostat Suppresses Hypoxia Signaling by Modulating Nuclear Translocation of Hypoxia Inducible Factor 1 Alpha. *Oncotarget* **2017**, *8*, 56110–56125. [CrossRef] [PubMed]

359. Trayanor, A.M.; Dubey, S.; Eickhoff, J.C.; Kolesar, J.M.; Schell, K.; Huie, M.S.; Groteluschen, D.L.; Marquette, S.M.; Hallahan, C.M.; Weeks, H.R.; et al. Vorinostat (NSC# 701852) in Patients with Relapsed Non-Small Cell Lung Cancer: A Wisconsin Oncology Network Phase II Study. *J. Oncol.* **2009**, *4*, 522–526. [CrossRef] [PubMed]

360. Krug, L.M.; Kindler, H.L.; Calvert, H.; Manegold, C.; Tsa0, A.S.; Fennell, D.; Öhman, R.; Plummer, R.; Eberhardt, W.E.; Fukuda, K.; et al. Vorinostat in Patients with Advanced Malignant Pleural Mesothelioma Who Have Progressed on Previous Chemotherapy (VANTAGE-014): A Phase 3, Double-Blind Randomized, Placebo-Controlled Trial. *Lancet Oncol.* **2015**, *16*, 447–456. [CrossRef]

361. Vansteenkiste, J.; Van Cutsem, E.; Dumez, H.; Chen, C.; Ricker, J.L.; Randolph, S.S.; Schöffski, P. Early Phase II Trial of Oral Vorinostat in Relapsed or Refractory Colorectal, or Non-Small Cell Lung Cancer. *Invest. New Drugs* **2008**, *26*, 483–488. [CrossRef] [PubMed]

362. Ramalingam, S.S.; Maitland, M.L.; Frankel, P.; Argiris, A.E.; Koczysw, M.; Giltitz, B.; Thomas, S.; Espinoza-Delgado, I.; Vokes, E.E.; Gandara, D.R.; et al. Carboplatin and Paclitaxel in Combination with either Vorinostat or Placebo for First-Line Therapy of Advanced Non-Small-Cell Lung Cancer. *J. Clin. Oncol.* **2010**, *28*, 56–62. [CrossRef]

363. Choi, C.Y.H.; Wakelee, H.A.; Neal, J.W.; Pinder-Schonack, M.C.; Yu, H.-H.M.; Chang, S.D.; Adler, J.R.; Modlin, L.A.; Harsh, G.R.; Solits, S.G. Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial. *Int. J. Radiat. Oncol. Biol. Phys.* **2017**, *99*, 16–21. [CrossRef] [PubMed]

364. Reguart, N.; Rosell, R.; Cardenal, F.; Cardona, A.F.; Isla, D.; Palmero, R.; Moran, T.; Rolfo, C.; Pallares, M.C.; Insa, A.; et al. Phase I/II Trial of Vorinostat (SAHA) and Erlotinib for Non-Small Cell Lung Cancer (NSCLC) Patients with Epidermal Growth Factor Receptor (EGFR) Mutations after Erlotinib Progression. *Lung Cancer* **2014**, *84*, 161–167. [CrossRef]

365. Han, J.-Y.; Lee, S.H.; Lee, G.K.; Yun, T.; Lee, J.Y.; Hwang, K.H.; Kim, J.Y.; Kim, H.T. Phase I/II Study of Gefitinib (Iressa®) and Vorinostat (IVORI) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. *Cancer Chemother. Pharmacol.* **2015**, *75*, 475–483. [CrossRef]
386. Manegold, C.; Dingemans, A.-M.C.; Gray, J.E.; Nakagawa, K.; Nicolson, M.; Peters, S.; Reck, M.; Wu, Y.-L.; Brustugun, O.T.; Crinò, L.; et al. The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. *J. Thorac. Oncol.* 2017, 12, 194–207. [CrossRef] [PubMed]

387. Shiraishi, Y.; Kishimoto, J.; Tanaka, K.; Sugawara, S.; Daga, H.; Hirano, K.; Azuma, K.; Hatajì, O.; Hayashi, H.; Tachihara, M.; et al. Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients with Advanced Nonsquamous Non-Small-Cell Lung Cancer. *Clin. Lung Cancer* 2020, 21, 472–476. [CrossRef] [PubMed]

388. Taylor, M.H.; Lee, C.-H.; Makker, V.; Rasco, D.; Dutcus, C.E.; Wu, J.; Stepan, D.E.; Shumaker, R.C.; Motzer, R.J. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. *J. Clin. Oncol.* 2020, 38, 1154–1163. [CrossRef]

389. Nishio, M.; Horai, T.; Horiike, A.; Nokihara, H.; Yamamoto, N.; Takahashi, T.; Murakami, H.; Yamamoto, N.; Koizumi, F.; Nishio, K.; et al. Phase 1 Study of Lenvatinib Combined with Carboplatin and Paclitaxel in Patients with Non-Small-Cell Lung Cancer. *Br. J. Cancer* 2013, 109, 538–544. [CrossRef]